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Abstract
High-risk neuroblastoma is characterized by an aggressively metastatic phenotype and five-year survival
rates of approximately 40%. Half of all high-risk patients experience disease relapse which remains
incurable. Recent studies have identified an enrichment of mutations in the RAS-MAPK pathway upon
relapse that are potentially sensitive to MEK1/2 inhibition with drugs such as trametinib. Although
trametinib is a potent MEK1/2 inhibitor, single-agent therapy invariably encounters de novo or acquired
bypass mechanisms that allow for disease progression. The central goal of this dissertation was to
contribute to the understanding of compensatory signaling mechanisms adopted by RAS-MAPK aberrant
neuroblastomas in response to MEK1/2 inhibition. Here, we interrogated the role of the Hippo pathway
protein YAP in intrinsic trametinib resistance and discovered that YAP1 gene knockout sensitized
neuroblastoma cells to trametinib. Further exploration into this mechanism showed that significantly
reduced expression of E2F and MYCN gene signatures promoted G1 phase cell cycle arrest. This study
also investigated novel TEAD palmitoylation inhibitors as inhibitors of YAP activity in combination with
trametinib. Of the three compounds tested, one showed synergy with trametinib across three RAShyperactivated neuroblastoma cell lines. To evaluate other signaling adaptations driving trametinib
resistance, we performed a high-throughput screen to identify synergistic trametinib drug combinations in
six RAS-hyperactivated neuroblastoma cell lines. The top drug targets with broad efficacy in at least three
cell lines were HMG-CoA reductase inhibitors, or statins, and three epigenetic inhibitors. The principal
finding of these studies was the observation of synergy between trametinib and two statins in two
neuroblastoma cell lines. However, no synergy was detected between trametinib and epigenetic inhibitors,
suggesting a false positive result. Altogether, this dissertation provides evidence of two synergistic
trametinib drug combinations in RAS-hyperactivated neuroblastoma that can be explored in the clinic.
These findings underscore the importance of YAP activity in response to trametinib in RAS-driven
neuroblastomas, as well as the potential for harnessing the pleiotropic effects of TEAD palmytoilation
inhibition and/or statins in a trametinib combination. Continued functional characterization of potential
targets of resistance will build upon these efforts to improve clinical responses of relapsed
neuroblastoma to trametinib combinatorial therapies and contribute to the larger field of MEK inhibitor
bypass mechanisms in cancer.
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ABSTRACT
EXPLOITING ACQUIRED RESISTANCE MECHANISMS TO MEK INHIBITION IN RASACTIVATED NEUROBLASTOMA
Grace E. Coggins
Dr. John M. Maris

High-risk neuroblastoma is characterized by an aggressively metastatic phenotype
and five-year survival rates of approximately 40%. Half of all high-risk patients
experience disease relapse which remains incurable. Recent studies have
identified an enrichment of mutations in the RAS-MAPK pathway upon relapse that
are potentially sensitive to MEK1/2 inhibition with drugs such as trametinib.
Although trametinib is a potent MEK1/2 inhibitor, single-agent therapy invariably
encounters de novo or acquired bypass mechanisms that allow for disease
progression. The central goal of this dissertation was to contribute to the
understanding of compensatory signaling mechanisms adopted by RAS-MAPK
aberrant neuroblastomas in response to MEK1/2 inhibition. Here, we interrogated
the role of the Hippo pathway protein YAP in intrinsic trametinib resistance and
discovered that YAP1 gene knockout sensitized neuroblastoma cells to trametinib.
Further exploration into this mechanism showed that significantly reduced
expression of E2F and MYCN gene signatures promoted G1 phase cell cycle
arrest. This study also investigated novel TEAD palmitoylation inhibitors as
inhibitors of YAP activity in combination with trametinib. Of the three compounds
tested, one showed synergy with trametinib across three RAS-hyperactivated
neuroblastoma cell lines. To evaluate other signaling adaptations driving
vi

trametinib resistance, we performed a high-throughput screen to identify
synergistic trametinib drug combinations in six RAS-hyperactivated neuroblastoma
cell lines. The top drug targets with broad efficacy in at least three cell lines were
HMG-CoA reductase inhibitors, or statins, and three epigenetic inhibitors. The
principal finding of these studies was the observation of synergy between
trametinib and two statins in two neuroblastoma cell lines. However, no synergy
was detected between trametinib and epigenetic inhibitors, suggesting a false
positive result. Altogether, this dissertation provides evidence of two synergistic
trametinib drug combinations in RAS-hyperactivated neuroblastoma that can be
explored in the clinic. These findings underscore the importance of YAP activity in
response to trametinib in RAS-driven neuroblastomas, as well as the potential for
harnessing the pleiotropic effects of TEAD palmytoilation inhibition and/or statins
in a trametinib combination. Continued functional characterization of potential
targets of resistance will build upon these efforts to improve clinical responses of
relapsed neuroblastoma to trametinib combinatorial therapies and contribute to the
larger field of MEK inhibitor bypass mechanisms in cancer.
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CHAPTER 1: INTRODUCTION
I. Neuroblastoma
A pediatric cancer of the developing sympathetic nervous system,
neuroblastoma arises from the neural crest during early embryogenesis (Hoehner
JC, 1996). The neural crest is a temporary structure that forms along the dorsal
neural plate during gastrulation. This structure is comprised of highly migratory
pluripotent neural crest stem cells that give rise to a variety of cell types in four
anatomical categories: cardiac, enteric, trunk, and head (Liu and Cheung, 2016,
Gammill and Roffers-Agarwal, 2010). Neuroblastoma originates along the
migratory route of sympathoadrenal precursor cells that differentiate into adrenal
chromaffin cells and sympathetic ganglion cells of the trunk, ultimately forming
neurons that line the ventral roots of the spinal cord and chromaffin cells of the
adrenal medulla and melanocytes (Matthay, 2016, Liu and Cheung, 2016, Gammill
and Roffers-Agarwal, 2010). As a result, primary tumors can be located anywhere
located along the sympathetic nervous system, but the most common site is the
adrenal gland in 40% of cases.
Neuroblastoma is characterized by remarkable clinical heterogeneity, with
survival rates varying widely based on the age of diagnosis, initial disease burden,
and biological characteristics of the tumor. Although neuroblastoma is classified
as an ultra-orphan disease, with <1,000 newly diagnosed cases each year in North
America, it is the most common extracranial solid tumor diagnosed in childhood
(Howlader N, 2011; Maris, 2007). The biological features of neuroblastoma tumors
1

can be used to stratify cases and predict overall prognosis. At diagnosis,
neuroblastoma typically has a low somatic mutational burden and is instead
considered a copy number-driven malignancy. Tumors frequently harbor genomic
instability in the form of segmental chromosomal copy number alterations and focal
copy number alterations, particularly MYCN gene amplification. Copy number gain
of 17q and loss of 1p are correlated with MYCN amplification, while loss of 11q is
inversely correlated with MYCN amplification (Matthay 2016, Maris 2007).
However, both MYCN amplification and 11q loss are both associated with highrisk disease and poor prognosis (Schwab M, 1983; Brodeur GM, 1984; Seeger
RC, 1985). According to the International Neuroblastoma Risk Group Staging
System, neuroblastomas are stratified according to the overall risk of relapse
(Cohn SL, 2009). Low-risk neuroblastomas are localized and biologically favorable
tumors (see below) with no other sites of disease. Intermediate-risk neuroblastoma
is a heterogeneous group that does not fall neatly into low- or high-risk. Rather, it
includes unresectable solid tumors with favorable biological characteristics as well
as metastatic disease without MYCN amplification in infancy. Approximately 50%
of all neuroblastomas are classified as high-risk, typically presenting as a primary
tumor with widely distant metastases. Approximately 99% and 95% of low- and
intermediate-risk neuroblastomas, respectively, are cured with little to no cytotoxic
therapy, whereas <50% of high-risk neuroblastomas are cured despite intensive
therapy (Maris JM, 2007, Matthay, 2016). Disease burden is combined with other
prognostic indicators, such as age, to further define risk groups. The median age
2

of diagnosis is 18 months, which serves as a demarcation of overall prognosis.
Patients younger than 18 months generally have better overall survival rates and
are associated with lower risk, while patients >18 months are typically categorized
as high-risk (Maris, 2007, Matthay, 2016).
The diversity inherent to neuroblastoma necessitates distinct treatment
guidelines, ranging from little to no therapeutic intervention to intense, multi-modal
therapy with toxic side effects. Low risk neuroblastomas frequently only require
surgery, and intermediate risk neuroblastomas are typically treated with surgery
and low-dose chemotherapy. These interventional methods are highly effective,
achieving survival rates of nearly 90% (Oberthuer A, 2015; Maris JM, 2010). High
risk neuroblastomas, however, require aggressive therapy that begins with highdose chemotherapy and surgery, followed by consolidation therapy consisting of
autologous hematopoietic stem cell transplantation and radiotherapy to induce the
remaining disease into remission (Matthay, 2016, Maris, 2007). Patients then
receive maintenance chemotherapy to prevent a relapse from recurring. In spite of
this therapy regimen, high-risk neuroblastoma has a survival rate of only 40%. This
devastating statistic is largely due to the high rate of relapse, with over half of highrisk neuroblastomas recurring and becoming incurable (Oberthuer A, 2015; Maris
JM, 2010). Patients receiving treatment for high-risk neuroblastoma experience
serious side effects, including myelosuppression, insufficient weight gain, and
renal dysfunction. This is compounded by the neurological and musculoskeletal
long-term side effects, as well as the increased risk of a secondary malignancy,
3

impaired growth, chronic kidney disease, and infertility (Maris JM, 2010).
Altogether, the physical toll of the treatment for high-risk disease combined with a
poor prognosis presents a clear rationale for the design of novel therapeutic
approaches.

II. Mutational Landscape in Neuroblastoma
Novel targeted therapies have shown immense promise in some cancers
with “druggable” oncogenic drivers. Broader access to and advances in
sequencing technologies has exponentially increased our ability to detect and
identify germline and somatic mutations. Defining the landscape of somatic and
germline mutations has enabled the clinical development of targeted inhibitors for
treating neuroblastoma.
Hereditary neuroblastoma is extremely rare and accounts for 1-2% of all
neuroblastoma cases. In 80-90% of familial cases of neuroblastoma, gain-offunction germline mutations in the receptor tyrosine kinase ALK are drivers of
tumorigenesis (Mosse, 2008). For patients with identified ALK driver mutations,
ALK inhibitor therapy has produced impressive results Bresler SC, 2011;
Schonherr C, 2011; Heuckmann JM, 2011; Carpenter EL, 2012). Loss of function
mutations in PHOX2B, a master regulator neural crest development, causes 5%
hereditary cases of neuroblastoma that is associated with other comorbidities of
nervous system development including congenital central hypoventilation
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syndrome and Hirschsprung disease (Maris, 2007). The remaining ~5% of
hereditary cases remain unexplained.
A series of major efforts to define the spectrum of genetic mutations in highrisk neuroblastoma identified ALK, PTPN11, and ATRX as the most commonly
mutated genes and additional low-frequency mutations in MYCN and NRAS.
(Cheung NV, 2012; Molenaar JJ, 2012; Pugh TJ, 2013; Sausen M, 2013).In a
follow-up study, whole genome sequencing of 23 paired diagnosis and relapse
tumor samples identified mutations in both primary and relapse samples, with an
average of 28% of shared mutations in the primary and relapse tumors (Eleveld,
2015). Unbiased pathway analysis of the relapse samples indicated an enrichment
for mutations in genes associated with the RAS-MAPK signaling pathway in 18/23
relapse samples (78%) (Eleveld, 2015). These mutations included two RTKS, ALK
and FGFR1, a RAS-GAP, NF1, an oncogenic tyrosine phosphatase, PTPN11, and
four pathway kinases, HRAS, KRAS, NRAS, and BRAF. Subsequent clonality
analyses determined that RAS-MAPK pathway mutations were present in
subclonal populations in the majority of primary tumors and were retained upon
relapse, suggesting that positive selection in response to standard of care therapy
set the stage for eventual relapse (Eleveld, 2015). This discovery not only
expanded our understanding of neuroblastoma genetics between diagnosis and
relapse, but also offered new hope for the treatment of patients with relapsed
neuroblastoma.

5

III. RAS-MAPK Pathway
The RAS-MAPK pathway is a complex and critical cellular signaling network
that regulates proliferation, growth, survival, differentiation, and apoptosis. This
pathway has been extensively studied for its role in oncogenic signaling and
tumorigenesis. The primary downstream effector proteins of the RAS-MAPK
pathway are ERK1/2 kinases, which exert their function on a variety of substrates
such as transcription factors, cell cycle components, kinases, and membrane
proteins (Fig. 1-1) Negative regulation of the RAS-MAPK pathway also serves an
important role in regulating normal pathway function, and loss of this tumor
suppressive function can promote RAS hyperactivation.
Germline mutations in RAS-MAPK pathway genes cause several important
cancer predisposition syndromes. Noonan Syndrome and neurofibromatosis type
1 are both autosomal dominant disorders that predisposes individuals to
developing pediatric cancers (Tidyman, 2010). In Noonan Syndrome, germline
mutations in four genes have been identified (PTPN11, KRAS, SOS1, and CRAF),
although more genes are expected to be identified as drivers in this disease. Of
these four genes, PTPN11 (SHP2) is associated with approximately 50% of all
Noonan Syndrome cases and promotes RAS hyperactivation when activating
mutations are present (Fig. 1-1) (Tidyman WE, 2009). In a smaller subset of
Noonan’s Syndrome cases, gain-of-function mutations in SOS1, as RAS-GEF,
KRAS, and CRAF directly promote hyperactivation of RAS-MAPK pathway
signaling (Tidyman WE, 2009). In addition, neurofibromatosis 1 is one among the
6

most common genetic conditions and is caused by inactivation of the NF1 gene
(Tidyman WE, 2009). The NF1 tumor suppressor protein functions as a RAS-GAP,
but loss-of-function germline mutations render the protein unable to promote the
conversion of RAS-GTP to the inactive form, leading to RAS hyperactivation
(Williams VC, 2009).
Somatic mutations causing constitutive activation of one or more pathway
components are extremely common in many types of human cancer, including
pancreas, colon, lung, and ovary organ sites (Santarpia, 2012). Two adult neuralcrest derived cancers, non-small cell lung cancer (NSCLC) and melanoma, also
frequently show RAS-MAPK pathway mutations. Melanomas frequently present
BRAF V600E (66%) mutations and NRAS (15%), whereas one-third of NSCLCs
are NRAS-mutated (Liu, 2018).
Efforts to target the RAS-MAPK pathway pharmacologically have been met
with mixed results. Until recently, the RAS proteins were largely considered to be
“undruggable” based on its function as a molecular switch with no clear cleft or
groove for inhibitor binding. Furthermore, the extremely high affinity of RAS for
GTP renders competitive inhibition nearly impossible. Early approaches the
pharmacologically inhibit RAS focus on targeting the post-translational
farnesylation that is required for RAS function and tethering to the plasma
membrane. Farnesyl transferase inhibitors (FTI) were developed to prevent this
enzymatic modification and showed promising early preclinical results. After two
different FTIs failed to show clinical efficacy, it was discovered that geranyl7

geranylation could compensate for the loss of NRAS and KRAS farneyslation
(Basso AD, 2006; Berndt N, 2011; Ryan MB and Corcoran RB, 2018). The failure
of FTIs underscores the difficulty of targeting a small G-protein and highlights the
promising potential for inhibiting downstream RAF and MEK proteins.
Two RAF inhibitors have been approved for single-agent treatment of BRAF
V600E/K mutant melanoma: vemurafenib and dabrafenib. Both second-generation
RAF inhibitors show improved selectivity for mutant BRAF but are limited by the
phenomenon of paradoxical ERK activation (Lorentzen HF, 2019). If the RAF
inhibitor is at a non-saturating concentration, drug-free RAF proteins can interact
with MEK and promote downstream activation of ERK. Furthermore, in the case of
non-V600E BRAF mutants, dimeric RAF complexes can evade inhibition due to
decreased binding affinity for the second partner (Poulikakos PI, 2010; Liu, 2018;
Durrant and Morrison, 2018). Thus, the inherent redundancy within the function of
RAF proteins allows the pathway to bypass BRAF inhibition.
For this reason, the development of MEK inhibitors has accelerated despite
the rarity of MEK1/2 mutations in human cancers. Three MEK1/2 inhibitors are
approved for combination with RAF inhibitors to treat cancer, but the only MEK1/2
inhibitor approved for single-agent use is trametinib (Yaeger R and Corcoran RB,
2019). Trametinib is a non-competitive inhibitor of MEK1/2 that functions by
binding to an allosteric pocket adjacent to the ATP-binding site. Binding of
trametinib causes a conformational change in the MEK1/2 protein structure that
occludes the ATP binding pocket and prevents kinase activation. Not only does
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trametinib have sub-nanomolar affinity for both MEK1 and MEK2, but it also has
fewer off-target interactions compared to other ATP mimetic kinase inhibitors.
Trametinib was the first FDA-approved MEK inhibitor in 2013 and was
indicated for the treatment of BRAF V600E/K-mutated metastatic melanoma (Liu,
2018). In the METRIC trial (NCT01245062), single agent trametinib significantly
increased progression-free survival by over 3 months compared to standard
chemotherapy, as well as improved overall survival rate (81% vs. 67%) and
complete or partial responses (22% vs. 8%) (Wright and McCormack, 2013).
Beyond overall survival, the effects of single-agent RAF or MEK1/2 inhibition
shows dramatic but transient clinical responses. While trametinib remains the only
MEK1/2 inhibitor indicated for single-agent treatment of BRAF V600E/K-mutant
melanoma, two additional MEK1/2 inhibitors, binimetinib and cobimetinib, have
also reached FDA-approval. Combination therapy has shown the ability to
overcome drug cytostasis and is preferentially used to treat RAS- or RAF-mutant
cancers over single-agent therapy.
Based on this early success of in melanoma, the efficacy of trametinib was
assessed in preclinical neuroblastoma models. Although gain-of-function ALK
mutations activate RAS-MAPK pathway signaling, cell lines with ALK mutations
were the least sensitive to trametinib in vitro and in vivo of all RAS-MAPK pathway
mutated cell lines (Eleveld, 2015, Umapathy, 2017). Trametinib was most potent
in RAS-mutated cell lines, followed closely by NF1-mutated cell lines and xenograft
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models. However, this activity is transient and cytostatic in vitro, necessitating
further therapeutic approaches to achieve sufficient antiproliferative effect.

Figure 1-1. The RAS-MAPK signaling pathway in cancer.

Figure 1-1: Pathway activation is initiated by the binding of an extracellular ligand
to receptor tyrosine kinases (RTKs) and receptor dimerization and
transautophosphorylation. These phosphorylation sites serve as docking sites for
adapter proteins which recruit guanine nucleotide exchange factors (GEFs) to the
plasma membrane. The interaction of RAS proteins with GEFs accelerates the
conversion of RAS from the inactive GDP-bound to the active GTP-bound state.
Activated RAS is able to initiate an array of important downstream pathways,
including the canonical RAF-MEK-ERK kinase cascade. RAS (NRAS, KRAS,
HRAS) phosphorylates and activates RAF (ARAF, BRAF, and CRAF), which then
phosphorylates and activate MEK1/2 (MAPK kinase). MEK1/2 phosphorylate
ERK1/2 (MAPK), which serve as the ultimate effector kinases.
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IV. MEK Inhibitor Drug Combination Design
Encouraged by the prolonged survival achieved by MEK1/2 inhibition,
continued efforts have focused on combining trametinib with rationale targeted
inhibitors to improve survival outcomes. The goal of combination therapy is to
eliminate alternate routes of survival to single-agent therapy, thereby crippling the
ability of a cancer cell to develop therapeutic resistance. Although MEK1/2
inhibition has proven to be effective in the context of RAS-MAPK pathway
hyperactivation, the efficacy of individual drug combinations appears to be much
more dependent on the signaling milieu of specific cancer cell types.
One approach to developing MEK1/2 inhibitor drug combinations has been
to target alternate kinases within the RAS-MAPK pathway. This double-hit
approach is predicated on the assumption that resistance occurs through ERK
reactivation and loss of feedback inhibition. In BRAF V600E/K malignant
melanoma, the combination of BRAF and MEK1/2 inhibition has been proven
effective and is now FDA-approved. Vemurafenib, dabrafenib, and the most recent
RAF inhibitor to gain FDA-approval, encorafenib, are approved for combination
treatment with MEK1/2 inhibitors cobimetinib, trametinib, and binimetinib,
respectively (Lorentzen HF, 2019).

In a randomized phase III clinical study

(NCT01597908) of BRAF V600E/K metastatic melanoma, patients were randomly
assigned to receive either a combination of trametinib and RAF inhibitor,
dabrafenib, or single-agent RAF inhibitor, vemurafenib (Robert, 2015). The
objective response rate was 64% in the combination group and 51% in the single11

agent vemurafenib group alone. Based on these results, combined BRAF and
MEK1/2 inhibition was able to overcome pathway reactivation to improve upon
overall survival. Unfortunately, a vast amount of survival data collected from many
clinical trials suggests that BRAF inhibitors are largely ineffective in models with
wild-type BRAF alleles (Robert, 2015). BRAF mutations are rare in neuroblastoma,
so combined inhibition of BRAF and MEK1/2 in is unlikely to be efficacious in the
vast majority of neuroblastomas.
Another mechanism implicated in resistance to MEK1/2 inhibition is
collateral activation of PI3K/AKT pathway signalling, seemingly due to upstream
RTK activation promoting parallel pathway activation. In KRAS-mutant preclinical
models of colon, pancreatic, lung, and melanoma cancer cell lines, synergy was
observed between an AKT inhibitor, MK-2206, and MEK1/2 inhibitor, selumetinib
(Tolcher, 2014). This effect was also observed in a KRAS-mutant colorectal cancer
xenograft model, but not in a BRAF V600E melanoma xenograft model. Building
on these results, numerous clinical trials have been established to test the
combination of a MEK1/2 inhibitor and PI3K inhibitor in cancer. One study in
particular, a phase I study of the combination of MK-2206 and selumetinib, was
conducted and showed partial responses in 3/13 KRAS-mutant NSCLC patients
and 1/2 ovarian cancer patients, but no objective responses were seen in KRASmutant colorectal cancer (Tolcher, 2014). These results underscore the complex
heterogeneity between cancer types with similar driver mutations
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In neuroblastoma specifically, there have also been ongoing efforts to
identify drug combinations partners in models with RAS-MAPK pathway
hyperactivation. Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) was
shown to confer resistance MEK1/2 inhibition. A MEK1/2 inhibitor, binimetinib, and
a CDK4/6 inhibitor, ribociclib, were observed to have therapeutic synergy across a
panel of neuroblastoma cell line models (Hart, 2016). In murine xenograft models,
the combination of binimetinib and ribociclib contributed to tumor growth delay and
prolonged survival over single-agent or vehicle treatment (Hart, 2016). Based on
this preliminary evidence, the Next Generation Personalized Neuroblastoma
Therapy (NEPENTHE, NCT02780128) Phase I clinical trial was devised to
sequence each patient’s individual tumor to identify actionable genetic mutations.
If a mutation in either ALK, CDK4/6, or the RAS-MAPK pathway is discovered, they
receive targeted therapy (with ceritinib, ribociclib, and/or trametinib). Despite the
preclinical success of MEK1/2 and CDK4/6 dual inhibition, it was not well-tolerated
in the clinic and was abandoned by Novartis. This project aims to build upon
previous progress by investigating alternate MEK1/2 inhibitor drug combination
strategies to achieve better clinical responses and improve survival outcomes for
relapsed neuroblastoma.

V. YAP-Hippo Pathway
In this dissertation, Chapters 2 and 3 focus on the involvement of the Hippo
pathway protein YAP in promoting de novo resistance to trametinib in RAS driven
13

neuroblastoma. The Hippo pathway was first identified in Drosophila to control
organ growth during development. Overexpression of Yki, the Drosophila ortholog
of

the human Yes-associated protein (YAP), caused massive overgrowth of

epithelial structures (Huang, 2005). In humans, YAP is the primary effector protein
regulated by the upstream Hippo pathway (Fig. 1-2). The Hippo pathway can be
activated by a host of upstream signals, including mechanotransduction (the
process by which cells sense and convert mechanical stimuli into biochemical
signals), cell density, mitogen-activated signaling, and cell-cell contact. As a coactivator, YAP can bind to transcription factors such as the TEAD family of
transcription factors, to promote transcription of YAP target genes, including CTGF
(connective tissue growth factor) and CYR61 (cysteine-rich angiogenic inducer 6)
(Zhao, 2007; Zhang, 2011). TAZ, a paralog of YAP, is known to have both
overlapping and independent functions as YAP and is regulated by similar
mechanisms via phosphorylation.
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Figure 1-2. YAP and the Hippo signaling pathway in cancer.

A

B

Figure 1-2. A) Mechanotransduction, cell density, mitogen-activated signaling, and
cell-cell contact can activate MST1/2 kinases, which phosphorylate and activate
LATS1/2 kinases. LATS1/2 then phosphorylate YAP at S127, which recruits 14-33 protein binding and is retained in the cytoplasm. Subsequent YAP
phosphorylation events recruit SCF, an E3 ubiquitin ligase. Upon polyubiquitination, YAP is flagged for proteasomal degradation and elimination. If the
upstream Hippo pathway is inactive and YAP remains in an unphosphorylated
state, it is able to translocate into the nucleus. The YAP protein structure lacks
nuclear localization signal and translocates into the nucleus through nuclear pores,
although the regulation of YAP nuclear transport has not been fully described
(Wang, 2016b). Upon entering the nucleus, YAP can function as a co-activator or
co-repressor of transcription. B) LATS1/2 phosphorylate YAP at five serine
residues in the YAP protein, indicated by yellow circles with “S” in the center.
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In cancer, YAP has been described as both an oncogene and a tumor
suppressor in a cell type-specific manner. YAP has been described as a stemnesspromoting factor in liver, intestinal, and skin stem cell populations (Hindley CJ,
2016). In other nervous system cancers, increased activation of YAP has been
shown to promote proliferation and tumorigenesis (Fernandez-L 2009; Orr, 2011).
High expression of YAP in breast cancer and colorectal cancer correlates with high
histological grade, metastasis, and poor overall survival (Zanconato, 2016).
Furthermore, liver-specific overexpression of YAP in in mice causes hepatomegaly
and hepatocellular carcinoma tumor formation (Dong, 2007). Reduced LATSmediated phosphorylation and inactivation of the Hippo pathway is well-supported,
but the rarity of inactivating pathway mutations in human cancers suggests that
alternate regulatory mechanisms may be at play (Harvey, 2013; Wang Y, 2018).
YAP can also be regulated by Rho-GTPases, actin dynamics, G-protein coupled
receptor (GPCR) signaling, and metabolism, all of which may be altered in a
cancer cell (Zanconato, 2016). Nevertheless, loss of LATS/12 diminishes the
ability of each of these signaling modalities to regulate YAP activity via
phosphorylation, suggesting that the LATS1/2 is the primary upstream regulator of
YAP regardless of the causal signaling input (Zanconato, 2016).
The extent of oncogenic YAP signaling as a driver of tumorigenesis has only
recently been elucidated with the advent of omics tools to study somatic Hippo
pathway alterations (Wang Y, 2018). Molecular profiling of data from the Cancer
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Genome Atlas (TCGA) identified 19 Hippo core pathway gene alterations.
Amplification of STK3 (MST2) and WWTR1 (TAZ) were the most frequent somatic
copy number alterations, followed by TEAD4, YAP1, and STK4 (MST1) (Wang Y,
2018). In fact, the most frequently amplified gene in cervical squamous cell
carcinoma was YAP1. The tumor suppressive function of LATS1/2 was consistent
with the observation of deep deletions in LATS1/2. However, somatic mutations in
YAP1 and WWTR1 (TAZ) are rarely found but have been discovered at low
frequencies (Wang Y, 2018). Furthermore, loss-of-function truncating mutations in
neurofibromatosis type 2 gene, NF2, were observed and have been shown to drive
oncogenic Hippo pathway activation (Bianchi AB, 1995; Li W, 2014; Sekido Y,
1995; Wang Y, 2018).
Investigation of YAP in neuroblastoma had not been extensively explored
until very recently, but literature suggests that YAP functions as an oncogene to
promote cellular proliferation, survival, and, metastasis (Yang, 2017, Seong,
2017). Although YAP expression was not diagnostic across a large cohort of
neuroblastoma patients, a YAP pathway signature was prognostic of patient
outcome (Seong, 2017). This observation is supported by evidence of upregulated
YAP transcriptional activity in relapsed neuroblastomas compared to matched
primary tumors (Schramm, 2015). Further, mice injected with YAP/TAZ-depleted
neuroblastoma cells experienced a significant reduction in metastases and an
increase in survival compared to control cells (Seong, 2017). Altogether, these
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data suggest that YAP signaling may be particularly relevant to relapsed
neuroblastoma.
Although YAP is not predicted to be a primary driver of neuroblastoma
development, recent literature suggests that it may be highly relevant in the context
of RAS-MAPK mutated cancers. Using a pooled shRNA screen, YAP was
discovered as genetic dependency in response to MEK1/2 inhibition in BRAF
V600E-mutated NSCLC cells (Lin, 2015). In response to trametinib, growth
inhibition of these cells increased by approximately 30% upon YAP1 knockdown
(Lin, 2015). In this study, investigators focused primarily on BRAF V600E-mutated
cells from a variety of cancers, including neural-crest derived NSCLC and
melanoma, but discovered that cells with KRAS and NRAS mutations were also
more sensitive to trametinib upon YAP knockdown (Lin, 2015). In two KRASaddicted colon cancer and lung cancer cell lines, YAP was shown to rescue cell
viability and promote resistance in response to inducible KRAS knockdown. KRAS
and YAP were shown to converge on the transcriptional regulation of a subset of
genes promoting epithelial-mesenchymal transition (EMT) (Shao, 2014). Despite
this evidence for YAP playing a role in RAS-activated cancer cell response to
MEK1/2 inhibition, the precise signaling mechanisms remain inconclusive.
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VI. Research Aims
Innovation Statement
Although there have been incremental improvement in long-term outcomes for
patients with neuroblastoma, there is an ongoing and urgent need for more precise
and effective therapies. Here, we sought to identify intrinsic resistance
mechanisms to MEK1/2 inhibition through parallel oncogenic pathways in RASdriven neuroblastoma, with the major ultimate goal of discovering synergetic drug
combinations. This project evaluates YAP as a potential contributing factor to
acquired trametinib resistance in neuroblastoma and the utility of novel YAP
activity inhibitors as potential partners of a therapeutic combination. We
hypothesized that reducing YAP transcriptional activity would improve sensitivity
to trametinib in RAS-driven neuroblastoma cell lines. In addition, this project
utilized a high-throughput drug screen for alternate drug combinations for the
treatment of a variety of RAS-MAPK pathway aberrant neuroblastomas. We
hypothesized that a large-scale survey of pharmacological compounds would
define potentially unknown compensatory mechanisms in response to trametinib
treatment. Overall, the goal of the project was to identify potential trametinib drug
combinations for translation to the NEPENTHE Phase I clinical trial at the
Children’s Hospital of Philadelphia (CHOP). The functional characterization of
potential targets of acquired resistance builds upon ongoing efforts to better
understand clinical responses of relapsed neuroblastomas to trametinib;
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furthermore, this project aims to contribute to the larger field of MEK1/2 inhibitor
bypass mechanisms in cancer.

Specific Aim 1: Evaluate the role of Hippo pathway protein YAP as a major
modulator of resistance to MEK1/2 inhibition in relapsed neuroblastoma

Specific Aim 1A: Investigate the contribution of YAP-Hippo pathway signaling to
trametinib efficacy in RAS-driven neuroblastoma cell lines
I observed the effect of trametinib on YAP phosphorylation and cellular localization.
Using CRISPR-Cas9 genetic editing and lentiviral overexpression, I modulated
YAP expression in neuroblastoma cell lines to assess sensitivity and determine
underlying signaling mechanisms. I hypothesized that YAP knockout would
sensitize RAS-driven neuroblastoma cell lines to trametinib and improve overall
efficacy.

Specific Aim 1B: Determine if combined MEK1/2 inhibition and YAP activity
inhibition is synergetic in RAS-driven neuroblastoma cell lines
I tested novel inhibitors of TEAD palmitoylation, which is critical for YAP/TEAD
transcriptional activity, in combination with trametinib in two RAS-driven
neuroblastoma cell lines to evaluate synergy. I analyzed the effect of TEAD
palmitoylation inhibitors on YAP target gene expression as a single-agent and in
combination

with

trametinib.

I

hypothesized
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that

inhibiting

YAP/TEAD

transcriptional activity in combination with trametinib would produce synergy in
RAS-driven neuroblastoma cell lines.

Specific Aim 2: Identify synergistic drug combinations with trametinib for preclinical
validation
I designed and performed a high-throughput drug screen using a library of >3,000
compounds to identify effective trametinib drug combinations across a panel of
RAS-MAPK aberrant neuroblastoma cell lines. I performed data analysis to narrow
down the list of possible drug combinations for preclinical validation. I hypothesized
that profiling a large drug library would reveal specific and potentially unknown
signaling dependencies in response to trametinib in RAS-driven neuroblastoma
cell lines.

Significance
The proposed work is innovative because it is the first study to comprehensively
explore druggable routes of intrinsic resistance to trametinib in RAS-driven
neuroblastomas for preclinical validation and clinical application. The functional
characterization of potential targets of resistance builds upon ongoing efforts
to

better understand

clinical

responses

of

relapsed

neuroblastoma

to

trametinib and contributing to the larger field of MEK inhibitor bypass mechanisms
in cancer. This dissertation contributes to the larger field of trametinib treatment
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regimen design in cancer and has immediate relevance to ongoing and future
therapies for relapsed neuroblastoma patients.
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CHAPTER 2: ROLE OF HIPPO PATHWAY PROTEIN YAP1 IN RESISTANCE
TO MEK1/2 INHIBITION IN RAS ACTIVATED NEUROBLASTOMAS
This chapter presents work featured in article: Coggins, G.E., Farrel, A., Rathi,
K.S., Hayes, C.M., Scolaro, L., Rokita, J.L., Maris, J.M. (2019). The Hippo pathway
effector protein YAP1 modulated resistance to MEK1/2 inhibition in
neuroblastomas with hyperactivated RAS pathway signaling. Cancer Research.
Accepted for publication 9/24/19.
Please see end of chapter for all figures and tables.
I. Abstract
Relapsed neuroblastomas harbor an enrichment in mutations activating RASMAPK signaling pathway. The MEK1/2 inhibitor trametinib has shown tumor
growth delay, but not sustained regressions, in neuroblastoma preclinical models.
Recent studies have implicated the Hippo pathway transcriptional coactivator
protein YAP1 as an additional driver of relapsed neuroblastomas, as well as a
mediator of trametinib resistance in other cancers. We hypothesized that increased
YAP1 transcriptional activity is a mechanism of MEK1/2 inhibition resistance in
RAS-driven neuroblastomas. Here, we used a highly annotated set of high-risk
neuroblastoma cellular models to modulate YAP1 expression and RAS pathway
activation to test our hypothesis. In NLF (biallelic NF1 inactivation) and SK-N-AS
(NRAS Q61K) cell lines, trametinib caused a near-complete translocation of YAP1
protein into the nucleus at 72 hours. YAP1 depletion sensitized neuroblastoma
cells to trametinib, while overexpression of constitutively active YAP1 protein
induced trametinib resistance. The mechanism explaining YAP1 deletion
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sensitizing RAS-driven neuroblastomas to trametinib was significant enhancement
of G1/S cell cycle arrest, mediated through a depletion of MYC/MYCN and E2F
transcriptional output.

II. Introduction
Neuroblastoma is a malignancy of the developing sympathetic nervous
system (Hoehner JC, 2010; Park JR, 2010; Maris JM, 1999; Maris JM, 2007; Park
JR, 2013; Maris JM, 2010). Half of all diagnosed neuroblastomas are classified as
“high-risk”, for which cure rates remain low. Aggressive empiric multimodal
therapy, including surgery, chemotherapy, radiation therapy and more recently
immunotherapy have shown incremental improvements in survival rates at the cost
of a host of chronic health comorbidities in survivors. Relapse after standard of
care remains largely incurable (Maris JM, 2010; Cohn SL, 2009). Thus, there is an
urgent need for more effective and precise therapies.
The development of novel treatments has been hindered by the relative lack
of molecularly targetable genomic lesions. Recurrent kinase domain gain-offunction mutations in the ALK oncogene occur in 8-15% of all newly-diagnosed
neuroblastomas (Maris JM, 2007; Park JR, 2013; Maris JM, 2010; Cohn SL, 2009;
Mosse YP, 2008), but may be present in a much larger percentage of relapse
specimens (Eleveld TF, 2015; Padovan-Merhar OM, 2016; Schleiermacher G,
2014; Schramm A, 2015). Indeed, compared to matched primary tumors, relapsed
neuroblastomas have a significantly higher mutational burden, with clonal
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enrichment in mutations in RAS-MAPK pathway genes beyond ALK such as
NRAS, KRAS, BRAF, PTPN11 and NF1 (Eleveld TF, 2015; Padovan-Merhar OM,
2016; Schramm A, 2015). Neuroblastoma cellular models with these genetic
aberrations have elevated levels of phosphorylated ERK1/2 and are extremely
sensitive to the MEK1/2 noncompetitive inhibitor trametinib in vitro, with low
nanomolar IC50s (Eleveld TF, 2015, Rader J, 2013). However, single agent MEK
inhibition is cytostatic and results only in tumor growth delay in neuroblastoma
xenotransplantation models with RAS hyperactivation (Eleveld TF, 2015; Hart LS,
2017; Umapathy G, 2017), similar to the experience in multiple preclinical and
clinical settings with single agent inhibition of MAPK pathway mutated cancers
Lugowska I, 2015; Lito P, 2014; Lito P, 2013; Zhao Y, 2014). For this reason,
combination strategies are being pursued to avoid tumor escape from therapy and
improve long-term responses. Dual inhibition of MEK1/2 and rational targets, such
as BRAF, PI3K/AKT, and CDK4/6, have shown promise in other tumor types,
including neuroblastoma (Rader J, 2013; Hart LS, 2017; Lugowska I, 2015; Lito P,
2014; Lito P, 2013; Zhao Y, 2014; Yao Z, 2015), but in the latter case all xenografts
eventually escaped dual MEK and CDK4/6 inhibition (Lito P, 2013).
The hippo signaling pathway is considered tumor suppressive through
cytosolic sequestration of the transcriptional co-activator protein YAP1 (Huang J,
2005; Dong J, 2007; Overholtzer M, 2006). Activated YAP1 mediates diverse
biologic functions such as organ size, cellular proliferation, and cell survival (Chan
SW, 2011; Chen Q, 2015; Zhao B, 2007; Pan D, 2010; Yu FX, 2012; Wu S, 2003;
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Wei X, 2007). YAP1 dephosphorylation allows translocation into the nucleus and
interaction with TEAD family and other transcription factors to initiate transcription
of a multiple gene targets (Lei QY, 2008; Steinhardt AA, 2008; Chen L, 2010; LiuChittenden Y, 2012; Cottini F, 2014; Adler JJ, 2013; Rayego-Mateos S, 2015).
Several groups have reported that YAP1 may be involved in resistance to
trametinib in RAS-driven cancers (Kapoor A, 2014; Lin L, 2015; Shao DD, 2014;
Hong X, 2014; Slemmons KK, 2015). Recently, increased YAP1 activity was
reported

as

a

hallmark

of

relapsed

neuroblastoma

after

intensive

chemoradiotherapy (Schramm A, 2015; Zhao B, 2007). In addition, inhibition of
YAP1 signaling has also been shown to abrogate neuroblastoma metastasis in
preclinical models (Seong BK, 2017). Paradoxically, the YAP1 gene is located on
chromosome arm 11q, a region that shows frequent hemizygous deletion,
particularly in high-risk neuroblastomas without MYCN amplification (Attiyeh EF,
2005; Mlakar V, 2017). Here we explore the hypothesis that derepression of YAP1
is a critical mediator of resistance to MEK inhibition in neuroblastomas with
hyperactivated MAPK signalling.

III. Methods and Materials
Cell Culture and Chemicals
Human-derived neuroblastoma cell lines were obtained from the Children’s
Hospital of Philadelphia cell line bank, the Children’s Oncology Group, and the
ATCC (Harenza JL, 2017). Cells were cultured in RPMI-1640 medium containing
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10% FBS, 2 mM L-Glutamine at 37 °C under 5% CO2. The genomic identity of the
cell lines was confirmed using the GenePrint 24 (Promega, Guardian Forensic
Sciences) and cell lines were free of mycoplasma contamination. Trametinib
dissolved in DMSO (Cellagen Technologies #C4112-5s) was used for in vitro
assays, with 0.1% DMSO as a negative control treatment. All cell lines were
derived from deidentified neuroblastoma patient tumor samples and the Children’s
Hospital of Philadelphia Institutional Review Board agreed with the investigators
that this work is not considered human subjects research.
Cell Viability Assays
Cells were seeded in 96-well cell culture plates at 2,500-4,000 cells per well
depending on growth kinetics. Drug treatments were performed in triplicate 24
hours later over a six-log dose range (0.01-10,000 nM). IC50 values for trametinib
were calculated using area under the curve at 72 hours post-treatment. Cell
viability was assessed using CellTiter-Glo (Promega). Cell growth assays were
performed using the IncuCyte Live Cell Analysis System (IncuCyte ZOOM, Essen
Bioscience) with the 20x objective lens during a 72-hour treatment.
CRISPR-Cas9, Plasmids and Lentiviral Delivery
To produce YAP1-targeting CRISPR-Cas9 knockout cell lines, scrambled sgRNA
CRISPR/Cas9 All-in-One Lentivirus (ABM #K011) and the YAP1 sgRNA CRISPR
All-in-One Lentivirus Set (Human) (ABM #K2653115) targeting the YAP1 gene
(Accession Number: NM_1006106.4) were used. Virus with sgRNA targeting
sequence #1 (5’-GTGCACGATCTGATGCCCGG-3’) and sequence #2 (5’27

CGCCGTCATGAACCCCAAGA-3’) of the YAP1 TEAD binding domain were
selected for these experiments. To produce YAP1 knockout pools in SKNAS and
NLF, cells were transduced with lentivirus for the sgRNA against sequence #1
according to the manufacturer’s protocol. For NLF isogenic cell lines, a second
YAP1 knockout pool was produced using lentivirus targeting sequence #2. Two
single-cell clones were selected from each YAP1 knockout pool and grown into
stable isogenic cell lines. Antibiotic selection was performed using 1 µg puromycin
(Sigma, #P9620).

The lentiviral YAP-5SA overexpressing plasmid was produced by inserting the
YAP-5SA sequence from the MYC-YAP-5SA plasmid (Zhao B, 2007) (Addgene
#33091) into a lentiviral CMV-puro DEST vector (Campeau E, 2009) (Addgene
#39481) using the PCR Cloning System with Gateway™ Technology with
pDONR™221 & OmniMAX™2 Competent Cells (Invitrogen #12535029) according
to the manufacturer’s recommended protocol. For lentiviral production, the YAP5SA lentiviral plasmid was transfected in combination with the pMD2.G VSV-G
envelope expressing plasmid (Addgene #12260) and psPAX2 lentiviral packaging
plasmid

(Addgene

#12259).

Plasmids

were

transduced

at

equimolar

concentrations of 3 uM into HEK-293T cells (ATCC, CRL-3216) using
Lipofectamine 3000 (Thermo Fisher Scientific #L3000008). Viral supernatant was
harvested at 48 hours and was filtered using a 0.45 um filter and added to cells
with 3 µg polybrene. Antibiotic selection was performed using 1 ug puromycin.
Primers
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Sequencing primers for endogenous to detect mutations in both of the target
sequences in the endogenous YAP1 protein TEAD binding domain: YAP1_F (5’TAAAGAGAAAGGGGAGGCGG-3’)

and

YAP1_R

(5’-

CCGGGAAGAAAGAAAGGAAGA-3’). Primers for Gateway cloning were designed
according to the manufacturer’s recommendations to remove the YAP-5SA
sequence from the MYC-YAP-5SA retroviral plasmid with flanking attB sites.
These

primer

sequences

were:

YAP-5SA_F

(5’-GGGG

ACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGAACAAAAACTCATCTCA3’)

and

YAP-5SA_R

(5’-

GGGGACCACTTTGTACAAGAAAGCTGGGTCCTATAACCATGTAAGAAAGCT
TTCTTT-3’).
Western Blotting
Protein was isolated from whole cell lysates using lysis buffer containing 1X Cell
Lysis Buffer (10X from Cell Signaling, #9803), 2 mM PMSF (Cell Signaling,
#8553S), in 100% isopropanol, and 1% phosphatase inhibitor cocktails 2 (Sigma,
#P5726) and 3 (Sigma, #P0044). Protein concentration was determined using the
Bradford protein assay (Bio-Rad). Approximately 20 µg of protein were run on 415% gradient Tris-Glycine gels (Bio-Rad, #5671085) and transferred using the BioRad transfer system. Antibodies used for western blotting include (Cell Signaling,
unless otherwise indicated): YAP1 (D8H1X) (1:1000, #14074), p-YAP1 (S127)
(D9W2I) (1:500, #13008S), p-ERK (1:2000, #4370), ERK (1:2000, #4695), b-Actin
(1:5000, #4967S), RB (1:2000, #9309), p-RB (S807-811) (1:1000, #9307), PARP
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(1:1000, #9532), cleaved PARP (1:1000, #5625S), MYCN (1:2000, #9405S),
Caspase-3 (1:1000, #9662), TATA Box binding protein (TBP) (1:1000, Abcam
#ab818). Western blots were visualized using SuperSignal West Femto Maximum
sensitivity substrate (Thermo Fisher Scientific, #34095) and the FluorChem Q
chemiluminescent

imaging

system

and

FluorChemQ

software

v3.4.0

(ProteinSimple).
RNA isolation and RT-qPCR
RNA was isolated using the Qiagen miRNEasy Mini Kit (Qiagen). Reverse
transcription was performed using the iScript Select cDNA Synthesis Kit (Bio-Rad
#1708897). Quantitative PCR was performed using the Taqman 2X Master Mix
(Thermo Fisher #4304437) on 384-well plates using the 7900HT Fast Real-Time
PCR instrument (Applied Biosystems) and the SDS v2.4 software (Applied
Biosystems). Taqman probes (Thermo Fisher Scientific, #4331182) used included:
YAP1 (Hs00902712_g1) HPRT1 (Hs02800695_m1), GAPDH (Hs03929097_g1),
CTGF (Hs01026927_g1), CYR61 (Hs00155497_m1), CDK1 (Hs00938777_m1),
MCM4 (Hs00907398_m1), MCM6 (Hs00195504_m1), POLA1 (Hs00213524_m1),
CCNE1 (Hs01026536_m1), E2F1 (Hs00153451_m1).
Flow Cytometry
Samples for cell cycle analysis were collected after 72 hours of trametinib
treatment at the IC50 concentration of NLF (20 nM) and SKNAS (10 nM). Cells
were detached with versene (0.02% EDTA in HBSS), washed with PBS + 1% FBS,
fixed for approximately 10 seconds by adding ice cold 70% ethanol dropwise with
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constant vortexing, and stored at -20°C. Cells were stained using 1 uL FxCycle
Violet (Invitrogen #F10347) per 1 mL PBS and analyzed using the CytoFLEX LX
with 6 lasers (Beckman Coulter). Data analysis was performed using the FlowJo
v10 software as described previously (Hart LS, 2017).
RNA Sequencing
Cells were plated in triplicate and treated with 20 nM trametinib for 72 hours prior
to collection. Cells were lysed on the plate using the QIAzol lysis reagent (Qiagen
#79306) and homogenized with Qiashredder tubes (Qiagen #79654). RNA was
then isolated using the RNeasy Mini Kit (Qiagen #74104) according to the
manufacturer’s protocol and quality was determined using the TapeStation 2200
(Agilent Technologies). All 18 samples were of optimal quality and achieved RIN
scores of 10.0. RNA synthetic spike-ins were added to each sample (Hardwick SA,
2016), with Mix A added to the NLF sgCon samples and Mix B added to the NLF
YAP1-/- #1 and #4 samples. Library preparation was done using 1 µg of RNA using
the TruSeq Total mRNA Kit with Gold rRNA Removal Mix as recommended
(Illumina #15031048). All 18 samples were sequenced using v2 chemistry,
2x150bp, and run on one high-output flow-cell of an Illumina NextSeq 500
instrument. Libraries were demultiplexed, Illumina adapters were trimmed, and
FASTQ file generated using the Illumina NextSeq Control Software version 2.02.

Raw fastq files (n = 18) from RNA-sequencing data with an average sequencing
depth of 22 million reads were aligned to human hg19 primary assembly reference
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genome using the STAR aligner v2.5.3a (Dobin A, 2013). Gene expression was
quantified as Fragments Per Kilobase of transcript per Million mapped reads
(FPKM) and transcript per million (TPM) using RSEM v1.2.28 normalization and
Gencode v23 gene annotation (Li B, 2011). On an average, 88.05% reads were
uniquely mapped to the reference genome. Normalization of RNA expression
between samples was performed by analyzing the synthetic spike-in standards
using Anaquin software toolkit distributed by Bioconductor (Wong T, 2017).

Differential expression analysis was performed using the R package, DESeq2.
Values were log2-transformed and biological replicates (N=3) were averaged
within each cell line and treatment group. Differentially-expressed genes
underwent Gene Ontology analysis using the ToppFun tool from the ToppGene
Suite and the top 5 ontologies were chosen (Chen J, 2009). GSEA was performed
using the Molecular Signatures Database Hallmarks Gene Set collection and run
for 1,000 iterations with a FWER p value cutoff of <0.01. All RNA-sequencing data
have been deposited in the Gene Expression Omnibus under Accession Number
GSE130401.
Statistics
Group comparisons were determined with a two-tailed t-test with a significance
cutoff of p<0.05. Data analysis was performed using GraphPad Prism and R
Studio.
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IV. Results
Trametinib causes YAP1 nuclear translocation in RAS-MAPK activated
neuroblastoma cell lines
We selected 16 of the 39 cell lines recently profiled and reported by our
group based on YAP1 mRNA expression and mutation status (Harenza JL, 2017)
(Fig 2-1A). The majority, but certainly not all, of the lines with mutations in the
canonical MAPK pathway showed YAP1 mRNA and protein expression, but only
one of the seven ALK mutated lines, and this line (SKNSH) showed robust protein
expression in the absence of detectable YAP1 mRNA. MYCN amplification and
11q copy number alterations for each cell line can be found in Supplemental Table
S1. Given that phosphorylation status and subcellular location are inherent to
YAP1 transcriptional activity, we investigated whether trametinib alters YAP1
nuclear localization in two high YAP1 expressing cell lines, NLF and SKNAS.
Nuclear and cytoplasmic extracts of NLF and SKNAS were collected after 72 hours
of exposure to trametinib. We observed a reduction in cytoplasmic phosphorylated
YAP1 across the time course, and a concomitant enrichment of nuclear YAP1 (Fig.
2-1B and C). Together, these data suggest that trametinib treatment in YAP1expressing and MAPK mutant neuroblastoma models causes depression of the
hippo pathway resulting in rapid (days) translocation of YAP1 to the nucleus.
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Figure 2-1. Trametinib causes nuclear accumulation of unphosphorylated
YAP1 protein.

Figure 2-1 Legend: (A) Expression of YAP1 mRNA (FPKM) across a panel of
neuroblastoma cell lines with known RAS-MAPK pathway mutations indicated
above. Below, YAP1 (70 kD) is expressed in a subset of RAS-driven
neuroblastoma cell lines with a beta-actin (40 kD) loading control. (B-C) 72-hour
trametinib treatment of NLF (20 nM) and SKNAS (10 nM) causes nuclear
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translocation of YAP1 (70 kD) protein compared to TATA Box-binding protein
(TBP, 40 kD) (B), which was quantified using densitometry (C).

Loss of YAP1 expression sensitizes neuroblastoma cell lines to trametinib
To determine whether YAP1 plays a role in sensitivity to trametinib in
neuroblastoma, we selected two neuroblastoma cell lines, NLF (biallelic NF1
inactivation) and SKNAS (NRAS Q61K), which both harbor endogenous
hemizygous deletions of 11q and thus YAP1 (Harenza JL, 2017). We employed
lentiviral CRISPR-Cas9 gene editing to produce pools of YAP1 null NLF and
SKNAS cells. Lentivirus containing sgRNA targeted to the YAP1 TEAD binding
domain or a scrambled control (sgCon) were used to transduce cells
(Supplementary Fig. 2-S1A). We observed incomplete reduction of YAP1 mRNA
and protein expression in both NLF and SKNAS sgYAP1 pools (Supplementary
Fig. 2-S2A and B). Despite this modest reduction in expression, we next showed
that the canonical YAP1 target genes CTGF and CYR61 (Chan SW, 2011) were
significantly

downregulated

in

NLF

and

SKNAS

YAP1-depleted

cells

(Supplementary Fig. 2-S2C), suggesting a significant impact on YAP1-mediated
transcription. We next sought to determine the impact of trametinib exposure on
cell viability in the isogenic pairs differing in YAP1 transcriptional activity. We
observed that the response of these cell lines to trametinib treatment was directly
related to the degree of modulation of YAP1 target genes (Supplementary Fig. 2S2D). Sensitivity to trametinib shifted in both NLF and SKNAS upon YAP1
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depletion, with IC50s in SKNAS shifting from 6.57 nM in sgCon) to 0.81 nM in
sgYAP1 (p=0.0255), as well as in NLF, with IC50s shifting from 15.98 nM in sgCon
to 7.76 nM in sgYAP1 (p=0.0019) (Supplementary Fig. 2-S2D). The growth curves
for the sgCon and sgYAP1 lines plateau at 35% viability for both NLF and SKNAS,
which is expected for the control lines due to the cytostatic nature of trametinib.
However, it is clear that the modest reduction of YAP1 expression was not
sufficient to reduce viability at the highest dose of trametinib in neither NLF nor
SKNAS sgYAP1 lines (Supplementary Fig. 2-S2D).
We next selected for clonal YAP1 null NLF cell lines after serial dilution of
CRISPR/Cas9 edited cells and isolated four isogenic clones. Indel mutations were
confirmed by Sanger sequencing of genomic DNA, with single nucleotide
insertions present in NLF YAP1-/- lines #1 and #2, and a single nucleotide deletion
in NLF YAP1-/- line #4 (Supplementary Fig. 2-S1B). Conversely, NLF YAP1-/- line
#3 showed a mixed population flanking the PAM site. We investigated the effect of
YAP1 loss on cellular growth and observed a modest growth delay of 20% in the
NLF sgYAP1 line compared to the sgCon line (Supplementary Fig. 2-S3). NLF
YAP1-/- #2 and #3 mixed clone had comparable growth rates, but the mixed clone
reached a similar confluence as sgYAP1. NLF YAP1-/- #1 and #4 cells grew at the
slowest rate and only reached to 30-40% of sgCon confluence. All four NLF YAP/-

cell lines showed reduced mRNA expression, and three showed no detectable

protein by immunoblotting (Fig. 2-2A-B). The NLF YAP1-/- #3 mixed clone showed
reduced, but detectable, YAP1 protein expression but displayed increased
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phospho-ERK expression. Based on the Sanger sequencing results and protein
expression, the NLF YAP1-/- #3 mixed clone was excluded from subsequent
assays. After confirming repression of CTGF and CYR61 mRNA (Fig. 2-2C), we
determined trametinib IC50 values in the isogenic YAP1-/- cell lines. All three YAP1/-

lines were significantly more sensitive to trametinib than NLF sgCon or NLF

sgYAP1 pool, with IC50 values reduced from a median of 0.79 – 2.18 nM for the
three YAP1-/- (p<0.0001 ) versus 7.62 nM for the pooled sgYAP1 (p<0.0038)
compared to 15.58 nM for the sgCon (Fig. 2-2D and E).
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Figure 2-2. YAP1 knockout sensitizes neuroblastoma cell lines to
trametinib.

Figure 2-2 Legend: A) Four isogenic lines were established from the NLF sgYAP1
CRISPR pooled cell line. YAP1 expression is shown for NLF sgCon, sgYAP1 pool,
and YAP1-/- #1-4 (N=3). B) Immunoblots of NLF sgCon, sgYAP1 pool, and YAP1/-

#1-4 for YAP, p-YAP, p-ERK, ERK, and beta-actin. C) Expression of YAP1 target

genes, CTGF and CYR61, in NLF sgCon, sgYAP1 pool, and YAP1-/- #1-4. D-E)
IC50 curves for trametinib in NLF sgCon, sgYAP1 pool, and YAP1-/- #1-4 over a 6log dose range (D) and a graphical representation of IC50 values (E) of trametinib
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(N=3). Student’s t-test, * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P <
0.0001.

Constitutively active YAP1 overexpression induces resistance to trametinib in
MAPK pathway activated neuroblastoma cells
The YAP1 protein contains five HXRXXS motifs that are recognized and
phosphorylated by LATS1/2. Of these five sites, phosphorylation of S127 on YAP1
promotes binding with 14-3-3 which causes cytoplasmic retention of YAP1.
Mutating all five serine residues to alanine ablates the LATS1/2 phosphorylation
sites and yields a constitutively-active YAP-5SA protein (Zhao B, 2007). In order
to observe the effect of increased YAP activity in response to trametinib, we
overexpressed YAP-5SA cDNA in NB-EBc1 (KRAS G12D) and SKNFI (NF1
homozygous inactivation), which are both de novo YAP1 protein null cell lines (Fig.
2-1A, Fig. 2-3A). Forced high overexpression of YAP-5SA protein resulted in
variable changes in these cells with different genotypes, in terms of a slight
increase in p-YAP1 in the NB-EBc1, and p-ERK in SKNFI. We next confirmed the
upregulation of CTGF and CYR61 in both lines (Fig. 2-3B and C). YAP-5SA
overexpression induced resistance to trametinib, in which cell viability did not reach
50% in either YAP-5SA overexpressing line compared to the control IC50s in both
NB-EBc1 (73.03 nM, p<0.001), and SKNFI (16.94 nM, p<0.0001) (Fig. 2-3D and
E). We then forced YAP-5SA overexpression in NLF YAP1-/- #1 and #4 cell lines,
despite the known limitation that the YAP-5SA construct would be recognized and
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cut by the CRISPR-Cas9 machinery. Despite this, we were able to obtain modest
overexpression of constitutively active YAP1, and a likewise (albeit subtler)
induction of relative resistance to trametinib, partially rescuing the YAP1-/phenotype (Supplementary Fig. 2-S4A-C).
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Figure 2-3. YAP-5SA overexpression induces trametinib resistance in low
YAP-expressing neuroblastoma cell lines.

Figure 2-3 Legend: A) Immunoblots of NB-EBc1 and SKNFI empty vector and
YAP-5SA-overexpressing cells. Immunoblots were probed for p-YAP1 S127 (70
kD), total YAP1 (70 kD), phospho-ERK (42, 44 kD), total ERK (42, 44 kD), and
beta-actin (40kD). B-C) YAP1, CTGF, and CYR61 expression in NB-EBc1 (B) and
SKNFI (C) empty vector- and YAP-5SA-overexpressing cells. Relative mRNA
expression is represented on a log scale (N=3). Student’s t-test, * = P < 0.05, ** =
P < 0.01, *** = P < 0.001, **** = P < 0.0001. D-E) IC50 curves for trametinib between
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empty vector and YAP-5SA overexpressing NB-EBc1 (P < 0.001) (D) and SKNFI
(P < 0.0001) (D) cells (N=3). One-way ANOVA (F(3,74) = 18.69, P < 0.0001) with
Sidak multiple comparisons test.

YAP1 mediates resistance to trametinib in neuroblastoma cells with hyperactivated
MAPK signalling through transcriptional activation of E2F and MYC(N)
To better understand how YAP1 plays a role in trametinib sensitivity, we
performed RNA sequencing of NLF sgCon and two isogenic cell lines, NLF YAP1/-

#1 and #4. All three cell lines were treated in triplicate with 20 nM trametinib or

DMSO for 72 hours, at which time total RNA was isolated (Fig. 2-4A). After total
mRNA sequencing, we confirmed that the biological replicates clustered together
by principal component analysis (Supplementary Fig. 2-S5A). We next confirmed
that YAP1 and downstream transcriptional targets CTGF, and CYR61 mRNA
expression was suppressed as predicted in the RNA sequencing data
(Supplementary Fig. 2-S5B). Of note, expression of WWTR1, the gene encoding
the YAP1 paralog TAZ, follows the same trend as YAP1 and its target genes, which
confirms that TAZ expression is not being upregulated to compensate for YAP1
loss (Supplementary Fig. 2-S5B).
We next performed three distinct differential expression analyses using the
R package DESeq2 (Fig. 2-4B). Differentially-expressed genes were identified
between three distinct sets: 1) sgCon treated with either DMSO or trametinib
(Trametinib-specific), 2) sgCon and NLF YAP1-/- #4 treated with DMSO (YAP1-/specific), 3) sgCon + DMSO and NLF YAP1-/- #4 + trametinib (Combination of
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YAP1 loss and MEK inhibition). Differentially expressed genes in the Trametinibspecific and YAP1-/--specific groups were subtracted from the trametinib-treated
YAP1-/- gene list. This final dataset represented the 1,474 differentially expressed
genes that were unique to the combination of trametinib treatment in a YAP1-/model. Gene ontology analysis of the transcripts downregulated within this dataset
revealed cell cycle and DNA repair pathways as most significantly enriched (Fig.
2-4C). Gene set enrichment analysis (GSEA) of the 1,474 genes produced only
two significantly enriched gene sets with a family-wise error rate of <0.01: E2F and
MYC targets (Fig. 2-4D). Heatmaps of E2F and MYC target genes show reduced
expression of target genes in NLF YAP1-/- #1 and #4 compared to sgCon (Fig. 24E). The most striking decrease in expression occurred with trametinib treatment,
particularly in the NLF YAP1-/- #4 cell line (Fig. 2-4E). Importantly, NLF
neuroblastoma cells do not express MYC but do express MYCN, suggesting that
this gene set actually refers to MYCN gene targets. To test this, we performed an
additional GSEA using the WEI_MYCN_TARGETS_WITH_E_BOX gene set (Wei
JS, 2008) (Fig. 2-4F). We confirmed that MYCN gene targets are significantly
enriched in the list of differentially expressed genes, with a family-wise error rate
of <0.01 and a normalized enrichment score of -3.22. Expression of relevant cell
cycle and DNA replication and repair genes follow a pattern similar to the E2F and
MYC heatmaps (Fig. 2-4G). Changes in expression of E2F1 were more modest,
but MYCN expression increases upon YAP1 loss in control-treated NLF YAP1-/- #1
and #4. In response to trametinib, expression in NLF YAP1-/- #1 and #4 decreases
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to similar levels of control- and trametinib-treated NLF sgCon samples. We also
confirmed the change in MYCN protein expression, which follows a similar pattern
observed in the differential expression results in response to YAP1 loss and
trametinib treatment (Supplementary Fig. 2-S5C). In an effort to connect the
changes in MYCN expression to YAP-TEAD signaling, we identified the conserved
DNA-binding motif CATTCC which is shared by all four TEAD1-4 transcription
factors using the online JASPER tool (7th release, 2018 version) (Supplementary
Fig. 2-S6A). We queried the region surrounding the MYCN gene locus using
Integrated Genomics Viewer (IGV) and identified CATTCC sense sequences in
the MYCN promoter and the first intron, as well as an antisense CATTCC
sequence in the MYCN promoter (Supplementary Fig. 2-S6B). This observation
confirms that the TEADs are able to bind at the MYCN locus and the loss of YAPTEAD transcriptional activity upon YAP1 knockout may account for these changes
in MYCN expression.
To understand the differences in differential expression between the YAP1/-

#1 and #4 cell lines, a differential expression analysis was performed between

DMSO-treated YAP1-/- #1 and YAP1-/- #4. Gene ontology analysis identified an
enrichment of genes upregulated in YAP1-/- #4 related to mRNA splicing and cell
morphogenesis as the primary biological processes, whereas downregulated
genes YAP1-/-

#4 compared to YAP1-/-

#1 were relevant to adhesion and

angiogenesis (Supplementary Fig. 2-S7). GSEA was performed against the
MSigDB hallmark gene sets but it identified no significant gene set enrichment.
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Taken together, these results suggest that there are major cancer signaling-related
gene expression differences between the two YAP1-/- cell lines. Rather, it suggests
that the YAP1-/- #4 cell line is a more differentiated line with reduced adhesion and
angiogenic capacity.
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Figure 2-4. Increased trametinib sensitivity upon YAP1 loss is due to loss
of E2F and MYC target gene expression.
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Figure 2-4 Legend: A) Workflow of RNA sequencing experiment. NLF sgCon,
YAP1-/- #1 and #4 were treated in triplicate with either DMSO or 20 nM trametinib
for 72 hours and total RNA was isolated. B) Venn diagram showing shared genes
among three differential expression analyses: 1) Trametinib-specific: sgCon
DMSO vs. sgCon Tram, 2) YAP1-/- #4-specific: sgCon + DMSO vs. YAP1-/- #4 +
DMSO, and 3) YAP1-/- #4 + trametinib: sgCon + DMSO vs. YAP1-/- #4 + trametinib.
C) Top 5 gene ontologies represented among the 1,474 unique trametinib-treated
YAP1-/- #4 genes. D) Gene set enrichment analysis of the 1,474 unique trametinibtreated YAP1-/- #4 genes with a FWER p value cutoff of <0.01. E) Heatmaps of
FPKM values normalized by row for each gene represented in the E2F and MYC
target gene sets. F) Gene set enrichment analysis of the 1,474 unique trametinibtreated YAP1-/- #4 genes against the

WEI_MYCN_TARGETS_WITH_E_BOX

gene set. G) FPKM values among all 6 groups for a subset of E2F and MYC target
genes.

In order to validate these RNA sequencing results, we performed RT-qPCR
of five gene targets from Fig. 2-4G and expression follows the expected pattern
(Fig. 2-5A). We also tested this using the SKNAS sgCon and sgYAP1 pooled lines
treated with trametinib (or DMSO), which followed a similar pattern (Fig. 2-5B). The
reduction of target gene expression was less robust than in the NLF YAP1-/isogenic lines likely due to the mosaic YAP1 expression in the pooled CRISPR
line. Since many of the E2F and MYC target genes are involved in the cell cycle
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and DNA replication, we performed flow cytometry to examine DNA content after
72 hours of trametinib treatment. In response to trametinib, the NLF sgCon cells
displayed a minor increase in G1 arrest (Fig. 2-5C). Loss of YAP1 expression
caused a further increase in G1 arrest and an even greater increase in G1 arrest
upon trametinib treatment. In the NLF YAP1-/- #4, which had the most significant
decrease in YAP1 target gene expression, we observed that 90% of the cells were
arrested at G1 in response to trametinib (Fig. 2-5C). These data were verified in
the SKNAS pooled cells, but to a lesser degree as expected (Fig. 2-5D). We further
investigated whether or not the combination of YAP1 loss and trametinib treatment
causes apoptosis. We did not observe increases in cleaved PARP or cleaved
caspase 3 in the YAP1-/- cell lines treated with or without trametinib
(Supplementary Fig. S5C). From these data, we propose that trametinib induces a
change in cellular signaling that causes a reduction in YAP1 protein
phosphorylation and induces YAP1 nuclear translocation, where it can promote
the transcription of E2F and MYCN target genes. In the absence of nuclear YAP1,
trametinib treatment induces a significant reduction in E2F and M YCN target gene
expression. As a consequence, we have shown G0/G1 cell cycle arrest, thus
impairing the proliferative capacity of neuroblastoma cell lines (Fig. 2-5E).
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Figure 2-5. Trametinib treatment of YAP1-/- cells causes G1 cell cycle arrest.

Figure 2-5 Legend: (A-B) Expression of CDK1, MCM4, MCM6, POLA1, and
CCNE1 in NLF sgCon and YAP1-/- #1 and 4 (N=3) (A) and SKNAS sgCon and
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sgYAP1 (N=3)(B). Cells were treated with DMSO or trametinib (NLF 20 nM,
SKNAS: 10 nM). (C-D) Cell cycle analysis of NLF sgCon and YAP1-/- #1-4 (N=3)
(C) and SKNAS sgCon and sgYAP1 (N=3) (D) treated with DMSO or trametinib
(NLF: 20 nM, SKNAS: 10 nM) for 72 hours. Flow cytometry was performed to
detect the proportion of cells present in G1, S, and G2. (E) Proposed mechanism
of inhibiting MEK1/2 signaling and YAP1 activity in RAS-driven neuroblastoma.
Dot = phosphorylation. Student’s t-test, * = p<0.05, ** = p<0.01, *** = p<0.001, ****
= p<0.0001.

V. Discussion
Relapsed neuroblastomas remain largely incurable, but recent insight into
relapse-specific mutations provide an opportunity to develop targeted therapies
(Eleveld TF, 2015; Schramm A, 2015). Hyperactivation of the RAS pathway is a
common finding in relapsed neuroblastomas, suggesting this contributes to
resistance to standard up front chemoradiotherapy. MEK inhibition shows
cytostasis and eventual tumor outgrowth in neuroblastoma preclinical models,
highlighting the need to identify combination therapies for this subset of patients.
Here, we identify enhanced activation of Hippo pathway protein YAP1 as a
cellular adaptation to MEK1/2 inhibition in RAS-driven neuroblastomas. We show
that while only a subset of RAS-driven neuroblastoma cell lines express detectable
YAP1 protein, short-term exposure to trametinib induces the translocation of
unphosphorylated “active” YAP1 into the nucleus. The exact mechanism causing
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the reduction in YAP1 protein phosphorylation, as well as the mechanism for
nuclear translocation, remains to be defined. The latter may be a result of reduced
phosphorylated YAP1, although actin stress fiber formation has been reported to
cause nuclear translocation in response to BRAF inhibitor resistance (Kim MH,
2016). Therefore, there may be multiple mechanisms involved in the YAP1 protein
dynamics in response to MEK inhibition. In the YAP1-expressing neuroblastoma
cell lines, we discovered that YAP1 protein expression levels were directly related
to trametinib sensitivity. In YAP1 expressing cell lines, genetic depletion of YAP1
expression sensitized to trametinib, while overexpression of constitutively active
YAP1 induced trametinib resistance in neuroblastoma cell lines with undetectable
YAP1. This observation may be clinically useful, as YAP1 transcriptional activity
may explain the cytostatic effects of MEK inhibition in RAS-driven neuroblastoma.
This finding also supports the purported clinical relevance of YAP1 in this disease,
as neuroblastomas have been shown to acquire increased YAP1 transcriptional
activity upon relapse (Schramm A, 2015).
Our findings show that in cells with YAP1 edited out, E2F and MYCN target
gene sets were downregulated when MEK1/2 was inhibited. This result provides
additional biological value to the importance of the hippo pathway in conferring
resistance to RAS-MAPK pathway inhibition. Due to the low MYC expression in
NLF cells, we demonstrated that MYCN gene targets were differentially expressed
and that MYCN expression increased in response to YAP1 loss but decreased
when combined with MEK inhibition. TEAD4 has been reported to bind to a
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consensus site in the MYCN promoter and function in a YAP1-independent
manner in neuroblastoma cells (Rajbhandari P, 2018). It is possible that the
absence of YAP1 may allow the TEAD proteins to initiate an alternate gene
expression program. However, we observed that this effect is lost when combined
with MEK inhibition. Alternatively, MYCN has been shown to be regulated by E2F
proteins in neuroblastoma (Strieder V, 2003), which may indicate E2F1 target gene
expression as the primary cause of the gene expression changes causing the
observed G1 cell cycle arrest. The exact mechanism causing E2F gene target
expression to decrease remains unclear. YAP and TEAD have been reported to
cooperate with E2F by ChIP analyses to coordinate cell cycle gene expression
(Kapoor A, 2014). The loss of both MEK-activated and YAP-activated E2F-related
gene expression may contribute to the differential gene expression observed in
response to MEK1/2 inhibition and YAP1 depletion. Recent literature has also
shown that BRAF-inhibitor resistance can induce YAP activated E2F-related cell
cycle gene expression in an actin-dependent manner (Kim MH, 2016). Here, we
present data suggesting a similar effect may occur in the context of MEK inhibition
in neuroblastomas with RAS activation.
This study has important clinical implications because combinatorial
inhibition of MEK1/2 and YAP1 signaling could be an effective combination to
circumvent cellular reprogramming. While no hippo pathway modulating drugs are
currently be tested in the clinic, there is increasing interest within academia and
industry to develop inhibitors of YAP1 activity (Chan P, 2016). It is important to
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note that the clinical relevance of the combination of YAP1 and MEK inhibition in
neuroblastoma would be limited to tumors that both harbor RAS-MAPK pathway
mutations and express YAP1 (de novo and/or induced by MEK inhibition). As
inhibitors of YAP1 activity are developed, our data support the development of
combined MEK1/2 and YAP1 inhibition for neuroblastomas with hyperactivated
MAPK signalling.
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CHAPTER 3: COMBINATORIAL TARGETING OF THE RAS-MAPK AND
HIPPO PATHWAYS WITH MEK1/2 AND TEAD PALMITOYLATION
INHIBITORS
We will refrain from pursuing publication of this work until we receive compounds
optimized for in vivo mouse studies. This work was included in an AACR abstract
(#2886): Coggins GE, Scolaro L, Hart LS, Tang, TT, Post, LE, Maris, JM. The
Hippo pathway protein YAP mediates resistance to MEK1/2 inhibition in
neuroblastoma. Poster presented at: AACR Annual Meeting; 2019 Apr 2; Atlanta,
GA.
I. Abstract

TEAD autopalmitoylation has recently been discovered to be required for
binding to the Hippo pathway protein YAP to TEAD1-4 proteins and promoting
transcription of YAP-TEAD gene targets. Vivace Therapeutics has developed first
in-class potent small molecule inhibitors of TEAD palmitoylation. Based on our
findings in Chapter 2, we hypothesized that inhibitors of TEAD palmitoylation would
have synergistic anti-tumor activity with trametinib in RAS-hyperactivated
neuroblastomas. I tested the efficacy of TEAD palmitoylation inhibitor tool
compounds as single-agents and in combination with the MEK1/2 inhibitor
trametinib in a panel of RAS hyperactivated and control neuroblastoma cell lines.
To determine single-agent activity, cells were treated with a 4-log dose range of
three TEAD palmitoylation inhibitors: VT101, VT102, and VT103. As expected, no
single agent activity was observed in the cell lines tested, regardless of RASMAPK pathway status. Synergy studies were performed in three RAS hyperactive
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cell lines (NLF, SKNAS, and SKNFI) with combinations of VT101 or VT102 and
trametinib. Cells were treated in duplicate in a matrix format over a 5-dose constant
ratio range of either drug based on the IC50 (here denoted as X; 1/4X, ½X, X, 2X,
4X). Since no IC50 was able to be calculated for the TEAD palmytoilation inhibitors,
we empirically assigned X=1 uM. The combination of VT101 and trametinib
showed synergy across all three cell lines, but the combination of VT102 and
trametinib did not. This difference in sensitivity is likely due to differential TEAD14 specificity or promiscuity. These results further support the hypothesis that YAP
promotes intrinsic resistance to MEK1/2 inhibition in neuroblastoma models with
Ras-MAPK pathway mutations.

II. Introduction
The previous chapter provided the rationale for investigating the
combination of a MEK1/2 inhibitor and a YAP inhibitor in preclinical models of
relapsed neuroblastoma. Efforts to pharmacologically inhibit YAP in cancer models
have been largely unsuccessful. Verteporfin (VP) is a protophorphyrin compound,
which is FDA-approved as a photodynamic therapy for treatment of blood vessel
disorders of the eye, such as macular degeneration and myopia. VP was observed
to disrupt the YAP-TEAD interaction by selectively binding to YAP (Liu-Chittenden
Y, 2012). In addition, VP has been reported to function as a scaffold to increase
YAP interaction with 14-3-3 leading to cytoplasmic sequestration (Wang, 2015).
Subsequent in vitro studies showed that VP treatment caused a reduction in YAP,
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phospho-YAP (S127), CYR61, and CTGF protein expression in uveal melanoma
cells (Ma Y.-W, 2016). However, there are drawbacks to pursuing VP as a feasible
therapeutic candidate for treating YAP-driven cancers. In vitro studies in a
melanoma cell line suggested that VP could cause YAP protein degradation, but
this effect disappeared in VP-treated tumors from a transgenic melanoma mouse
model (Liu JW, 2019). Furthermore, VP is a porphyrin compound and facilitates
the formation of protein aggregates, which could cause cellular toxicity and
undesirable side effects in patients.
Rather than targeting YAP directly, recent progress has been made towards
understanding the dynamics of the protein-protein interaction between TEAD and
YAP. Autopalmitoylation was discovered to regulate the transcriptional activity of
the Hippo pathway and was shown to be necessary for TEAD binding to YAP but
not other transcriptional binding partners, such as the Vgll4 tumor suppressor
(Chan P, 2016). Furthermore, palmitoylation status did not affect TEAD localization
and therefore does not function as a membrane anchor like RAS farnesylation
(Chan P, 2016). Rather, autopalmitoylation was observed within a deep pocket
within the TEAD protein structure but did not interact with the YAP protein upon
binding. Chan P, et al. postulate that the palmitate group induces a TEAD
conformational change that is required for YAP binding.
The discovery of TEAD autopalmitoylation revealed a novel avenue for
inhibiting oncogenic YAP transcriptional activity. Vivace Therapeutics has
developed small molecule inhibitors of YAP-TEAD activity by selectively blocking
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the palmitoylation of TEAD1-4 proteins via high-throughput phenotypic profiling
(Tang TT, 2019). Subsequent optimization produced extremely potent compounds
with IC50s at single digit nM levels in cell-based assays and demonstrated reduced
palmitoylation in presence of purified recombinant TEAD proteins. Vivace
Therapeutics validated this mechanism in NF2-deficient mesothelioma cells with
YAP hyperactivity and discovered that the novel compounds reduced proliferation
in vitro and in vivo and were well-tolerated in murine models (Tang TT, 2019). The
efficacy of these compounds in a YAP-driven preclinical cancer model serves as
a strong foundation for the continued exploration of TEAD palmitoylation inhibitors
for clinical development. The company is continually evolving a series of
compounds with varying selectivity for individual TEAD proteins as well as panTEAD inhibitors for eventual application across a spectrum YAP- and TEAD-driven
diseases.
In collaboration with Vivace Therapeutics, we performed the first exploration of
the efficacy of TEAD palymitoylation inhibitors in combination with trametinib in
human cancer. This chapter builds on the conclusions from Chapter 2 and
observes the predicted lack of single-agent activity of TEAD palmitoylation
inhibitors in a panel of neuroblastoma cell lines. This study also demonstrates
combination drug synergy between trametinib and TEAD palmitoylation inhibitors
in three neuroblastoma cell lines, NLF (NF1 splice variant), SKNAS (NRas Q61K),
and SKNFI (NF1 null). I hypothesized that inhibiting YAP activity using TEAD
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palmitoylation inhibitors in combination with trametinib would be synergistic in Rasdriven neuroblastoma cell lines.

III. Methods and Materials
Cell Culture and Chemicals
Human-derived neuroblastoma cell lines were obtained from the Children’s
Hospital of Philadelphia cell line bank, the Children’s Oncology Group, and the
ATCC (Harenza JL, 2017). Cells were cultured in RPMI-1640 medium containing
10% FBS, 2 mM L-Glutamine at 37 °C under 5% CO2. The genomic identity of the
cell lines was confirmed using the GenePrint 24 (Promega, Guardian Forensic
Sciences) and cell lines were free of mycoplasma contamination. Trametinib
dissolved in DMSO (Cellagen Technologies #C4112-5s) was used for in vitro
assays, with 0.1% DMSO as a negative control treatment. Vivace Therapeutics
provided the TEAD palmitoylation inhibitors (VT101, VT102, and VT103), which
were received dissolved in DMSO to a stock concentration of 10 mM. All cell lines
were derived from deidentified neuroblastoma patient tumor samples and the
Children’s Hospital of Philadelphia Institutional Review Board agreed with the
investigators that this work is not considered human subjects research.

Cell Viability Assays
Cell growth assays were performed using the IncuCyte Live Cell Analysis System
(IncuCyte ZOOM, Essen Bioscience) with the 20x objective lens during a 72-hour
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treatment. IC50 values for trametinib were calculated using area under the curve at
7 days post-treatment. To detect cell viability, cells were seeded in 96-well cell
culture plates at 1,500-3,000 cells per well depending on growth kinetics. Drug
treatments were performed in duplicate 24 hours later over a 5 dose range based
on the cell line IC50 value at a constant ratio (DMS0, 1/4X, 1/2X, X, 2X, 4X, where
X = IC50). By plating the drugs in a matrix format, the efficacy of each combination
of drug concentrations was measured. Cell viability was assessed using CellTiterGlo (Promega).

Statistics
Drug combination synergy was calculated using Compusyn software based on the
Chou method of calculating drug synergy (Chou TC, 2006; Chou TC, 2010). IC50
values were determined using GraphPad Prism (v6) and performing a nonlinear
regression analysis using the “log(inhibitor) vs. response –Variable slope (four
parameters)” dose response equation at the 7-day time point for each
concentration.

IV. Results
TEAD palmitoylation inhibitors are not effective as single-agents in Rashyperactivated neuroblastoma cell lines
Based on the data shown in Chapter 2, we did not expect to see singleagent activity with TEAD palmitoylation inhibitors of YAP activity. In order to
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establish a baseline level of activity of TEAD palmitoylation inhibitors for
subsequent

synergy

assays,

we

selected

three

Ras-hyperactivated

neuroblastoma cell lines used in Chapter 2: NLF, SKNAS, SKNFI. We received
three TEAD palmitoylation inhibitors from Vivace Therapeutics that were identified
as VT101, VT102, and VT103. Cells were treated with over a 4-log dose range of
each drug and percent confluence was compared to a topotecan positive control.
In NLF cells, topotecan was potent in the low nanomolar range, but VT101
produced only a minimal response in the highest doses (Fig. 3-1A and B).
However, VT102 and VT103 had no effect on cellular growth in NLF (Fig. 3-1C
and D). Topotecan was similarly potent in SKNAS, but no effect on cellular
confluence was induced by any of the TEAD palmitoylation inhibitors (Fig.3-2A-D).
With these results in two high YAP-expressing cell lines, we selected a third low
YAP-expressing cell line, SKNFI, to test whether YAP expression levels affect
single-agent potency of TEAD palmitoylation inhibitors. Although topotecan
potency remained consistent, none of the TEAD palmitoylation inhibitors had a
significant effect on SKNFI confluence (Fig. 3-3A-D). In response to VT101 and
VT102, the effect of the 1nM treatment appeared to be an outlier in SKNFI due to
the lack of a response at higher concentrations (Fig. 3-3C-D). These results
suggest that single-agent inhibition of YAP activity in Ras-addicted neuroblastoma
cells is not an effective treatment.

60

Figure 3-1. Dose-response curves of VT101, VT102, and VT103 in NLF
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Figure 3-1 Legend: Dose-response curves performed in NLF over a 4-log dose
range of A) topotecan, B) VT101, C) VT102, and D) VT103. Percent confluence
over a 7-day assay was determined using a confluence mask in the IncuCyte
ZOOM software.
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Figure 3-2. Dose-response curves of VT101, VT102, and VT103 in SKNAS
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Figure 3-2 Legend: Dose-response curves performed in SKNAS over a 4-log dose
range of A) topotecan, B) VT101, C) VT102, and D) VT103. Percent confluence
over a 7-day assay was determined using a confluence mask in the IncuCyte
ZOOM software.
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Figure 3-3. Dose-response curves of VT101, VT102, and VT103 in SKNFI
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Figure 3-3 Legend: Dose-response curves performed in SKNFI over a 4-log dose
range of A) topotecan, B) VT101, C) VT102, and D) VT103. Percent confluence
over a 7-day assay was determined using a confluence mask in the IncuCyte
ZOOM software.
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We next sought to validate the observation that TEAD palmitoylaton is
necessary for interaction with YAP but not other binding partners (Chan P, 2016).
TEAD4 has been reported to function in a YAP-independent manner to promote
survival in the context of MYCN-amplification (Rajbhandari P, 2018). Knockdown
of TEAD4 caused a significant reduction in proliferation and colony formation
(Rajbhandari P, 2018). To test whether VT101, VT102, and VT103 harbor singleagent activity in RAS wild-type, MYCN-amplified neuroblastoma, we selected two
cell lines, Kelly and COG-N-519, for dose-response assays. Compared to
topotecan, no effect of percent confluence was observed in response to VT101,
VT102, or VT103 in Kelly (Fig. 3-4A-D). Similarly, the three TEAD palmitoylation
inhibitors had no effect on percent confluence in COG-N-519 (Fig. 3-5A-D).
Although these data look strikingly similar to that of the RAS hyperactivated cell
lines, we have validated the observation that inhibiting TEAD palmitoylation does
not affect YAP-independent signaling in MYCN-amplified neuroblastomas.
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Figure 3-4. Dose-response curves of VT101, VT102, and VT103 in Kelly
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Figure 3-4 Legend: Dose-response curves performed in Kelly over a 4-log dose
range of A) topotecan, B) VT101, C) VT102, and D) VT103. Percent confluence
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over a 7-day assay was determined using a confluence mask in the IncuCyte
ZOOM software.

Figure 3-5. Dose-response curves of VT101, VT102, and VT103 in COG-N519
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Figure 3-5 Legend: Dose-response curves performed in COG-N-519 over a 4-log
dose range of A) topotecan, B) VT101, C) VT102, and D) VT103. Percent
confluence over a 7-day assay was determined using a confluence mask in the
IncuCyte ZOOM software.

TEAD palmitoylation inhibitors and trametinib are synergistic in vitro
Building upon the observation in Chapter 2 that knocking down YAP
sensitized Ras-MAPK pathway mutated neuroblastoma cells to trametinib, we
tested whether TEAD palmitoylation inhibitors could recapitulate that effect. In
conversations with Vivace Therapeutics, VT103 was determined to be undesirable
for continued preclinical testing due to a lack of potency and an undesirable
pharmacological profile, so only VT101 and VT102 were tested for synergy with
trametinib. NLF, SKNAS, SKNFI cells were treated in a matrix format with
increasing doses of each drug at a constant ratio (1/4X, 1/2X, X, 2X, 4X, with
X=IC50). Due to the lack of potency of VT101 and VT102 as single-agents, no IC50
could be calculated and a concentration of X=1 uM. In all three cell lines, synergy
was tested between VT101 and trametinib, with synergy defined as a combination
index (CI) values <1. In NLF, the series of CI values corresponding to the equal
ratios of VT101 and trametinib were plotted against fraction of cells affected (Fig.
3-6A). Although this spread of CI values across the fraction affected is large, the
highest fraction affected value was produced by the highest concentration
combination. Importantly, all CI values analyzed in NLF were <1 and synergistic
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(Fig. 3-6B). Similar results were seen in SKNAS, in which all combinations were
synergetic, including the 5 equal ratio CI values (Fig. 3-6C and D). In SKNFI, all of
the CI values were below 1, but the fraction affected was high in all five equal ratio
combinations (Fig. 3-6E and F). This result suggests that the combination of YAP
and MEK1/2 inhibition in SKNFI is particularly potent.
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Figure 3-6. Synergy observed between trametinib and VT101 in NLF, SKNAS,
and SKNFI
NLF (NF1 splice variant)
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Figure 3-6 Legend: Synergy assays were performed by plating cells onto 96-well
plates and treating cells in a matrix format with 1/4X, 1/2X, X, 2X, and 4X dilutions
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of either trametinib or VT101, where X=IC50. For VT101, X=1 uM. Combination
index (CI) values were quantified based on cell viability using Compusyn. A) CI
values of equal ratio combinations are plotted against the cell viability fraction
affected in NLF. B) CI values are shown for each combination of trametinib and
VT101 in NLF. C) CI values of equal ratio combinations are plotted against the cell
viability fraction affected in SKNAS. D) CI values are shown for each combination
of trametinib and VT101 in NLF. E) CI values of equal ratio combinations are
plotted against the cell viability fraction affected in SKNFI. F) CI values are shown
for each combination of trametinib and VT101 in SKNFI.

In contrast to the synergy observed between VT101 and trametinib, no
synergy was detected between VT102 and trametinib (Fig. 3-7A-C). In fact, the CI
values were so exponentially large that they could not be calculated. In looking at
the fraction affected in NLF and SKNAS, it is clear that VT102 imposes no
additional effect on cell viability in combination with trametinib and appears to be
antagonistic (Fig. 3-7A and B). In SKNFI, combination of VT102 and trametinib
appeared to be antagonist based on the fraction of cells affected, although VT102
did appear to be more potent as a single-agent than in NLF or SKNAS (Fig. 3-7C).
Our data confirm that inhibiting YAP-TEAD activity with TEAD palmitoylation
inhibitors in combination with trametinib is synergistic, but that there are functional
differences between VT101 and VT102 that affect this synergistic relationship with
trametinib. Under our confidentiality agreement with Vivace Therapeutics, we are
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unable to disclose the specificity of TEAD palmitoylation inhibitor but we postulate
that the differences in synergistic activity may be related to inhibitor specificity for
TEAD1-4. To further validate the effect of combination of trametinib and VT101 in
RAS-hyperactive neuroblastoma, synergy assays in RAS wild-type, MYCN
amplified lines is planned but not yet completed.

Figure 3-7. No synergy observed between VT102 and trametinib in NLF,
SKNAS, or SKNFI
NLF (NF1 splice variant)
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Figure 3-7 Legend: Synergy assays were performed by plating cells onto 96-well
plates and treating cells in a matrix format with 1/4X, 1/2X, X, 2X, and 4X dilutions
of either trametinib or VT102, where X=IC50. For VT102, X=1 uM. Combination
index (CI) values were quantified based on cell viability using Compusyn but were
extraordinarily high and considered antagonistic. To demonstrate the lack of
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synergy between trametinib and VT102, values representing the fraction affected
are shown for each combination of trametinib and VT102 in A)NLF, B) SKNAS,
and C) SKNFI.

V. Discussion
In this chapter, I assessed the efficacy of combined MEK1/2 and TEAD
palmitoylation inhibition on cell viability of Ras-hyperactivated neuroblastoma cell
lines. RAS wild-type controls are ongoing. I first performed dose-response assays
in a panel of Ras-hyperactivated neuroblastoma cell lines to determine a baseline
activity measurement of the three compounds as single-agents. Inhibiting YAPTEAD activity alone did not significantly decrease cellular growth or confluence
over the seven-day period. This was not entirely surprising based on the growth
rates of the sgYAP1 and YAP1-/- #2 cell lines (Supplementary Fig. 2-S3), in which
the decrease in proliferation was not proportional to the degree of YAP knockdown.
In consultation with Vivace Therapeutics, VT103 was determined to be inferior to
the other two compounds due to a lack of potency and was not included in
subsequent experiments. I next validated previous reports of YAP-independent
TEAD activity in MYCN-amplified neuroblastoma by showing that inhibiting the
YAP-TEAD interaction via TEAD palmitoylation does not affect growth or survival
in RAS wild-type, MYCN-amplified Kelly and COG-N-519 neuroblastoma cell lines.
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To assess whether inhibiting TEAD palmitoylation would recapitulate the
YAP knockout from Chapter 2, I also tested for synergy between VT101 or VT102
and trametinib in a subset of RAS-hyperactivated neuroblastoma cell lines in a
seven-day period. Synergy was detected between VT101 and trametinib in NLF,
SKNAS, and SKNFI, but not between VT102 and trametinib. Furthermore, with
increasing concentrations of VT101 and trametinib, the fraction affected in each
cell line increased. Our findings suggest that TEAD palmitoylation inhibition is a
candidate for combination with trametinib in RAS-MAPK aberrant neuroblastomas.
As discussed in Chapter 2, this drug combination would only benefit patients with
tumors expressing YAP and harboring RAS hyperactivity.
The striking difference between VT101 and VT102 in combination with
trametinib suggests that the predicted differential sensitivity of each compound for
TEAD1-4 may be biologically relevant. If one or more TEAD transcription factors
are more relevant to intrinsic MEK1/2 inhibitor resistance than others, this could
expand upon our current mechanistic understanding. Understanding the exact
specificity of each compound will be immensely important for further studies of this
drug combination. In addition, investigating the effect of this combination on YAP
and phospho-YAP protein expression and cellular localization would provide
important context into YAP protein dynamics in response to abolished YAP-TEAD
binding capability. Further studies should also examine the effects of combined
TEAD palmitoylation and MEK1/2 inhibition on cell cycle arrest and apoptosis,
which would serve to validate our findings in Fig. 2-5C and D and Supplementary
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Fig. 2-S5C. Ultimately, an in vivo study using Ras-hyperactivated patient-derived
xenografts (PDX) will be an important means to test of the clinical potential of this
combination based on the efficacy and tolerability observed in mice.
This study represents a proof-of-concept validation of the relationship
between YAP and MEK1/2 in RAS hyperactive neuroblastoma. Our lab is
continuing to work closely with Vivace Therapeutics as they optimize compounds
with the proper pharmacokinetic and pharmacodynamic properties. We aim to test
these lead compounds in combination with trametinib in vitro and in vivo and
submit this story for publication.
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CHAPTER 4: HIGH-THROUGHPUT APPROACH TO DESIGNING
ALTERNATE MEK1/2 DRUG COMBINATIONS FOR RAS ACTIVATED
NEUROBLASTOMA
I. Abstract
I hypothesized that high-throughput profiling of a large drug library for
trametinib drug combination partners would reveal novel mechanisms of intrinsic
resistance to MEK1/2 in a panel of RAS-MAPK pathway hyperactivated
neuroblastoma. Cells were plated onto 384-well plates and treated with a library of
FDA-approved and investigational anti-cancer agents and either DMSO or
trametinib. By comparing the effect of the library compounds alone and combined
with trametinib, the strictly standardized mean difference (SSMD) for each
combination was used to rank and filter the top drug combinations in each cell line.
To identify a drug combination that would be broadly effective across the spectrum
of RAS-MAPK pathway mutations in neuroblastoma, I prioritized candidates that
were potent across a majority of the cell lines screened. HMG-CoA Reductase
inhibitors, including atorvastatin and lovastatin, were identified as the top drug
candidates in three cell lines. Synergy was observed in the combination of the
statins and trametinib in multiple cell lines, although the most synergistic
combinations required statin concentrations in the micromolar range, which is
typically not considered clinically relevant. These results suggest that statins may
be useful candidates for combination with trametinib, but additional validation of
other drug screen combinations is necessary. In summary, continued exploration
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of potential drug combinations will be critical for the preclinical development of
trametinib drug combinations and will help improve our understanding of the
cellular reprogramming events that drive de novo trametinib resistance in
neuroblastoma.

II. Introduction
In Chapters 2 & 3, I presented evidence that YAP expression determines
sensitivity to MEK1/2 inhibition in RAS driven neuroblastoma cell lines.
Furthermore, I showed that the combination of MEK1/2 and YAP activity inhibition
produced synergy. While we think this combination could improve survival rates of
children with relapsed neuroblastoma, the Vivace compounds are early in
development and there are many potential obstacles before first-in-human studies.
In order to identify other potential targeted inhibitors for combination with trametinib
(or other MEK1/2 inhibitors), we conducted a high-throughput screen (HTS) to test
the efficacy of combinations across five neuroblastoma cell lines with unique RASMAPK pathway aberrations, all resulting in hyperphosphorylated MEK and ERK.
In the wake of developments in genomics technologies, oncogenic driver
mutations and signaling pathway addictions have been characterized and
identified as putative therapeutic targets (Lawrence MS, 2014; Al-Lazikani B,
2012). Single-agent drug screens have produced expansive databases of
anticancer agents with activity in distinct cell lines and genomic profiles (Weinstein
JN, 1997; Greshock J, 2010; Barretina J, 2012; Garnett MJ, 2012). However, the
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potential for superior activity of a drug combination rather than a single-drug
therapy serves as the motivating force for developing a dual treatment strategy.
To this end, high-throughput screening offers an efficient and robust method of
uncovering novel signaling dependencies in response to single-drug treatment
(Sun X, 2013). Many screening approaches have been utilized to identify targets
for combination therapy, including CRISPR-based knockout, short-hairpin RNA, as
well as directly testing drug-drug combinations (Sun X, 2013; Han K, 2017;
Manchado E, 2016; Williams SP, 2017). In this study, we profiled a library of 3,045
compounds for synergistic combination with the MEK1/2 inhibitor trametinib.
I hypothesized that profiling a large library of drug compounds in
combination with trametinib would reveal previously unknown drivers of intrinsic
resistance to trametinib in a panel of neuroblastoma cell lines. By profiling a five
neuroblastoma cell lines, our goal was to capture a potential trametinib drug
combination that would exhibit potency in models with unique RAS-MAPK pathway
aberrations.

III. Materials and Methods
Cell culture
Cells were cultured in RPMI-1640 medium containing 10% FBS, 2 mM LGlutamine at 37 °C under 5% CO2. Cells were detached with versene (0.02%
EDTA in HBSS), washed with PBS + 1% FBS, and resuspended in culture media
for plating.
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Cell Viability Assays
Cells were seeded in 96-well cell culture plates at 2,500-4,000 cells per well
depending on growth kinetics. Drug treatments were performed in triplicate 24
hours later over a six-log dose range (0.01-10,000 nM). IC50 values for trametinib
were calculated using area under the curve at 72 hours post-treatment. Cell
viability was assessed using CellTiter-Glo (Promega).

Compound library and storage
The screening drug library was comprised of 3,045 compounds and was pre-plated
on 10 individual 384-well plates (Selleckchem). A complete list of drugs can be
found in Table 4-S1. On each plate, columns 1 and 23 contained 100% DMS0 as
a negative control and column 24 contained bortezomib as a positive control. Stock
plates were stored at -40°C and freeze-thaw cycles were kept below 10 to prevent
compound degradation. Trametinib dissolved in DMSO (Cellagen Technologies
#C4112-5s) was maintained at 10 mM concentration at -20°C.

High-throughput screening
Cells were plated onto 20 384-well assay plates using a Multidrop Combi Reagent
Dispenser (Thermo Scientific) at pre-determined plating densities for a 96-hour
assay for each cell line. Cells were incubated overnight in a humidity-controlled
incubator at 37°C and 5% CO2. Drugs from the compound library were plated at
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50 nl using the slotted pin tool (V&P Scientific) within the JANUS Automated
Workstation (Perkin Elmer). Each library plate was transferred to two assay plates,
which were then treated with either 50 nl 100% DMSO or 50nl trametinib at the
IC20 concentration for each cell line (NLF: 1nM, SKNAS: 0.5 nM, SKNFI: 2 nM, NBEBc1: 2 nM, and SKNSH: 1 nM). Altogether, 10 assay plates were treated with the
library compounds and DMSO and 10 assay plates were treated with the
combination of the library compounds and trametinib. Assay plates were incubated
at 37°C for 72 hours and cell viability was assessed using the ATPlite
Luminescence Assay (Perkin Elmer) and the EnVision Xcite Multilabel Plate
Reader (Perkin Elmer).

Data analysis
Data was analyzed using the Strictly Standardized Mean Difference (SSMD)
method of high-throughput screen analysis, in which the difference of the means
and the standard deviation of the difference between two populations is quantified
(Zhang XD, 2007; Williams SP, 2017). The following equation was used: SSMD =
(µ" $ µ%)
(

s(' ) s((

. In this screen, 10 library plates were used to treat 20 assay plates that

then received either DMSO or trametinib. Because only one replicate of the screen
was performed, (µ1 - µ2) corresponded to difference between the raw values for
each library compound treated in combination with DMSO (µ1) and trametinib (µ2).
To control for the variability within each library plate, the plate standard deviation
was determined using the standard deviations of all DMSO-treated (s" ) and
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trametinib-treated (s% ) sample values treated with corresponding library plates.
Altogether, 10 unique analyses were performed for each cell line specific to each
library plate.
Z-scores were also calculated for each drug combination to compare to the SSMD
method using the formula Z =

µ* $+
s*

, where µn refers to the mean of the trametinib-

treated negative control wells on each assay plate and s, refers to the standard
deviation of this mean.

Screen quality was assessed using a Z-factor measurement with the following
equation: Z-factor = 1 -

-(s. )s* )

µ. $µ*

, with p denoting positive control values and n

denoted negative control values. Z-factor scores between 0.5 – 1.0 were
considered to be excellent assays, with 1.0 being ideal. Scores between 0 – 0.5
were considered marginal, while <0 was considered to have too much overlap
between positive and negative controls to be useful.

For filtering, a set of guidelines were established to identify a synthetic lethal
combination. First, a cutoff was set to SSMD >3, indicating at least three standard
deviations from the mean. Next, the cutoff for the difference in normalized percent
inhibition (NPI) between the DMSO-treated and trametinib treated samples was
set to >20%, because the IC20 trametinib concentration would be expected to
reduce cell viability by 20%. Finally, the NPI of the library compounds treated with
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DMSO cutoff was set to -15 £ 0 ³ 15 to eliminate compounds that either induced
excessive growth or cell death as single-agents.
Statistics
Drug combination synergy was calculated using Compusyn software based on the
Chou method of calculating drug synergy (Chou TC, 2006; Chou TC, 2010). IC50
values were determined using GraphPad Prism (v6) and performing a nonlinear
regression analysis using the “log(inhibitor) vs. response –Variable slope (four
parameters)” dose response equation at the 7-day time point for each
concentration.

IV. Results
High-throughput combination screen design
We selected five neuroblastoma cell lines as representative models of the
most frequent RAS-MAPK pathway aberrations detected in neuroblastoma patient
samples: NLF (NF1 splice variant), SKNAS (NRAS Q61K), SKNFI (NF1 null), NBEBc1 (KRAS G12D), SKNSH (ALK F1174L). These five cell lines all been shown
to have basal hyperphosphorylation of ERK and are sensitive to trametinib in the
low nanomolar range (Hart LS, 2017). Although MEK1/2 inhibition is not potent in
most ALK-mutated neuroblastoma models, SKNSH is the most sensitive of the
ALK-mutated cell lines and was included. In an effort to identify a synthetic lethal
drug combination, we designed a HTS to test the effect of a library of 3,045
compounds, of which 27.8% are FDA-approved, 68.6% are not FDA-approved,
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and 3.5% are discontinued (Fig. 4-1A). Within this library, drugs can be classified
by their proposed class, including cancer, endocrine, epigenetic, GPCR, ion
channel, kinase, metabolism, microbiology, NSAID, protease, and other. The
compounds classified as “other” were largely inviable candidates for future use in
humans but served as tool compounds within this library. The layout of each library
plate included two DMSO negative control columns and one bortezomib positive
control column, with the remaining wells on the 384-well plate containing library
compounds (Fig. 4-1B).

Figure 4-1. High-throughput trametinib combination screen design
A

B

Cell plating on assay plates
(N=20)

DMSO

Bortezomib

Library Compounds

Compounds transferred from
each library plate (N=10) to 2
assay plates

trametinib
(N=10)

DMSO
(N=10)
72 hours

ATPlite

C
Cell Line

MAPK Pathway Status

Trametinib
IC20

NLF

NF1 1845 +1GàT splice variant

1 nM

SKNSH

ALK F1174L

1 nM

EBc1

KRAS G35A

2 nM

SKNAS

NRAS C181A

0.5 nM

SKNFI

NF1 homozygous deletion

2 nM

Figure 4-1 Legend: A) Schematic of high-throughput screen protocol. B) Library
plate layout including negative control (DMSO), positive control (bortezomib) and
sample library compounds on each plate. C) 72-hour IC20 values for each cell line
determined on a 384-well plate using ATPlite cell viability reagent.
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In an effort to identify potent drug combinations, the trametinib dose for the
HTS was determined by the trametinib IC20 in each cell line (Fig. 4-1C). Cell
viability results were analyzed to determine the quality of the data on each plate
using a Z-factor measurement. This scale ranges from 0-1.0, with 0.5-1.0
indicating an excellent assay, 0-0.5 indicating a marginal assay, and scores <0
negating the usefulness of the data. Across 20 plates tested for each cell line, only
8 total plates were considered marginal assays and 92% (92/100 plates) of the
screen being considered “excellent” (Supplementary Fig. 4-S1). The DMSOtreated SKNFI library plate 3 plate did receive a Z-factor score of 0, but because it
was not <0, we included it in this analysis. We next calculated z-scores and strictly
standardized mean difference (SSMD) scores as a dual method of analysis. The
SSMD scoring is more robust because it is less sensitive to outliers than z-scoring.
The SSMD was calculated using the difference of the DMSO and trametinibtreated values in combination with each compound and divided by the sample
standard deviation of the entire assay plate. We compared the z-scores and SSMD
scores for each cell line and determined that SSMD was a more robust indicator
of quality. For example, the entirety of the trametinib-treated combinations in
SKNFI was plotted using SSMD scores or Z-scores (Supplementary Fig. 4-S2A
and B). When z-scores were overlaid according to highest SSMD value to lowest,
it became clear that the high SSMD scores predicted activity in the trametinib
combinations more uniformly and with greater accuracy than high z-scores
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(Supplementary Fig. 4-S2C). Based on this comparison, SSMD scores were used
for further “hit” determination.
We next instituted a series of filtering steps to narrow down the list of viability
trametinib drug combinations. First, the cutoff for SSMD score was set to ³3, which
corresponded to a value three standard deviations from the mean of the assay
plate. However, only one compound in SKNSH achieved an SSMD score of >3, so
the cutoff for SKNSH was lowered to SSMD>2. Next, the normalized percent
inhibition (NPI) was calculated as the ratio of each sample to the negative control
on each plate. The NPI cutoff for DMSO-treated samples was set to -15 £ 0 ³ 15
to eliminate any compounds that caused excessive increases or decreases in cell
viability as single-agents. Because the IC20 concentration of trametinib was used,
we set a cutoff of >20% difference in NPI values between DMSO-treated and
trametinib-treated samples. The final list of top trametinib drug combinations for
each cell line was tabulated and further sorted by drug target, with one or more
drugs acting on each drug target (Fig. 4-2A). In order to identify a drug combination
that would be effective across cell lines with different RAS-MAPK pathway
alterations, we selected drug targets that were shared between at least 3 or more
cell lines (Fig. 4-2B).
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Figure 4-2. SSMD analysis reveals top drug targets for trametinib
combination
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Figure 4-2 Legend: SSMD scores were calculated to determine the top trametinib
drug combinations on each plate and in each cell line, with a cutoff of SSMD>3. A)
All combinations with SSMD>3 were compiled further categorized by unique drug
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targets and listed within each cell line. B) To identify a combination with broad
efficacy, drug targets that were present among the top combinations in 3 or more
cell lines were filtered. For each drug target, the number of corresponding unique
compounds are listed.

Validation of HMG-CoA Reductase inhibitors in combination with trametinib
HMG-CoA reductase is the rate-limiting enzyme of the mevalonate
pathway, an essential metabolic pathway in the biosynthesis of cholesterol. For
this reason, HMG-CoA reductase inhibitors, or statins, are commonly used to treat
hypercholesterolemia and adults and familial hypercholesterolemia in children
(Hindler K, 2006). Within the mevalonate pathway, statins prevent conversion of
HMG-CoA to mevalonic acid, which is later converted to farnesyl and geranylgeranyl intermediates. Because small G-proteins require post-translational
isoprenylation for membrane tethering and function, statins have been predicted
to be useful against cancer models with hyperactivated Rho, Rac, and RAS
(Hindler K, 2006).
To assess the value of a combination of trametinib and a statin, we first
determined the single-agent activity of statins in the five RAS-hyperactive
neuroblastoma cell lines tested in the screen (Fig. 4-3A and B). Both atorvastatin
calcium and lovastatin were most potent in NLF, with IC50 values in the nanomolar
range, while IC50 values in NB-EBc1, SKNAS, SKNFI, and SKNSH were in the
86

micromolar range (Fig. 4-3C). In general, all five cell lines were more sensitive to
atorvastatin calcium than lovastatin, although the differences in IC50 values did not
exceed two-fold.

Figure 4-3. Single-agent activity of statins in neuroblastoma cell lines.
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B
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Figure 4-3 Legend: 72-hour dose-response curves performed over a 6-log
dose range of in NB-EBc1, SKNAS, SKNFI, SH-SY5Y, SKNSH, and NLF treated
with A) Atorvastatin calcium and B) lovastatin. C) IC50 values calculated in
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GraphPad Prism corresponding to atorvastatin calcium and lovastatin in six cell
lines.

We next investigated whether the combination of trametinib and a statin is
synergistic in RAS-hyperactivated neuroblastoma. The two most sensitive cell
lines to single-agent atorvastatin calcium and lovastatin were NLF and NB-EBc1,
which were selected for synergy analysis (Fig. 4-3B). Unlike the synergy assays
performed in Chapter 2, only two trametinib concentrations (corresponding to the
IC20 and IC50 in each line) were tested in combination with five concentrations of
either atorvastatin calcium or lovastatin. Cell viability was analyzed, and synergy
was quantified using CI values. In NLF, all combinations of trametinib and
atorvastatin calcium were synergistic, as well as all combinations of trametinib and
lovastatin, with CI values <1. (Fig. 4-4A and B). Similarly, all combinations of
trametinib and atorvastatin calcium showed synergy in NB-EBc1 (Fig. 4-4C).
However, the combination of the IC20 trametinib dose and lower dose lovastatin in
NB-EBc1 was not synergistic, but rather antagonistic with CI values >1, while the
high doses of lovastatin did show synergy (Fig. 4-4D). Upon increasing the
trametinib dose to the IC50 concentration, all combinations of trametinib and
lovastatin were considered synergistic (Fig. 4-4D). Altogether, these results
suggest that combined inhibition of MEK1/2 and HMG-CoA Reductase is an
effective combination in RAS-hyperactivated neuroblastoma cell lines.
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Figure 4-4. Synergy observed between statins and trametinib in NLF and
NB-EBc1.
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Figure 4-4 Legend: Synergy assays were performed by plating cells onto
96-well plates and treating cells in a matrix format with 1/4X, 1/2X, X, 2X, and 4X
dilutions of either atorvastatin calcium or lovastatin, where X=IC50. For both statins,
X=1 uM. The IC20 and IC50 concentrations for trametinib in NLF (5 and 20 nM,
respectively) and NB-EBc1 (1.25 and 5 nM, respectively) were used. Combination
index (CI) values were quantified based on cell viability using Compusyn. A) CI
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values are shown for each combination of trametinib and atorvastatin calcium in
NLF.B) CI values are shown for each combination of trametinib and lovastatin in
NLF. C) CI values are shown for each combination of trametinib and atorvastatin
calcium in NB-EBc1. D) CI values are shown for each combination of trametinib
and lovastatin in NB-EBc1.

V. Discussion
In this chapter, I profile a large drug library for potential combination with
trametinib in RAS-hyperactivated neuroblastomas and assess the efficacy of
trametinib in combination with HMG-CoA reductase inhibitors. Combined
trametinib and atorvastatin calcium or lovastatin proved to be synergistic in RASaddicted neuroblastoma cell lines. Overall, these findings suggest that while HMGCoA reductase inhibitors may have potential in a trametinib drug combination,
further work must be done to interrogate alternate combinations from the screen
and validate drug combinations using patient-derived xenograft (PDX) mouse
models.
Our findings suggest that dual inhibition of MEK1/2 and HMG-CoA
reductase is consistent with reports from prior studies. One downstream
implication of inhibiting isoprenylation of oncogenic G-proteins is the reported
suppression of AKT activation, which can promote survival in response to MEK1/2
inhibitor therapy (Iizuka-Ohashi M, 2018). This evidence supports observations
that targeting PI3K, the direct upstream of activator of AKT, with ribociclib shows
90

therapeutic synergy with trametinib in neuroblastoma models and causes tumor
growth delay (Hart LS, 2016). Thus, statins may target multiple potential signaling
pathways related to intrinsic trametinib resistance. Unfortunately, the statin
concentrations required to achieve synergy with trametinib with in the low
micromolar range, which are not considered clinically-relevant concentrations.
Further testing with novel HMG-CoA Reductase inhibitors may yield improved
synergy efficacy and potency with trametinib. In addition, investigating the
pleiotropic effects of statins within cancer cells by assessing changes in gene
expression and post-translational modifications will improve our understanding of
trametinib-related therapy escape in neuroblastoma.
We also tested additional combinations of trametinib and epigenetic
inhibitors of HDAC6, EZH2, and DOT1L. We elected not present this data in this
chapter based on the lack of efficacy observed. The three compounds showed no
single-agent activity in vitro in NLF, SKNAS, SKNFI, or SKNSH. Meanwhile, the
data obtained from our synergy assays were inconsistent and suggested that these
combinations were highly antagonistic. This suggests that the combination of
trametinib and an epigenetic inhibitor was likely a false positive finding and
highlights the limitation of a HTS with only one replicate.
In conclusion, this study utilized an existing high-throughput screening
platform to survey a large library of compounds to identify trametinib drug
combinations for RAS-hyperactivated neuroblastoma. We had hoped to find novel
and immediately translatable drug candidates, but none emerged to date, which is
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unfortunately not limited to our system as combinatorial partners for MEK1/2
inhibition in other cancers have also been difficult to define. Of note, a potential
weakness of this study was the single replicate of the combination drug screen.
Edge effects on cell culture plates as well as natural biological variation could have
caused fluctuations in data that could have been interpreted more easily with
additional replicates. These data provide useful evidence for combinatorial
efficacy, but additional replicates or a larger validation effort would be necessary
to identify a viable trametinib drug combination for further preclinical evaluation. In
addition, expanding the panel of cell lines to include more models with different
RAS-MAPK aberrations would help define the broad usefulness of a combination.
Taken together, our data represents a step forward in understanding the signaling
adaptations in neuroblastoma cells in response to trametinib and supplementary
investigation will be necessary to fully validate clinically-useful therapeutic
combinations.
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CHAPTER 5: OVERALL DISCUSSION AND FUTURE DIRECTIONS
Within the neuroblastoma research field, the paucity of recurrent druggable
oncogenic driver mutations and genomic heterogeneity between and within tumors
has impeded the development of broadly effective targeted therapies. Rather than
focusing on low- or intermediate-risk neuroblastomas with good prognoses, or
even high-risk neuroblastomas at diagnosis, the purpose of this research was to
contribute meaningful insight into therapy design for relapsed neuroblastomas, for
which survival rates remain abysmally low, with the future goal of integrating
effective relapse therapies into frontline regimens to prevent relapse. This
dissertation work was centered around our discovery that RAS hyperactivation is
enriched in relapsed tumors and our assumption that mechanisms of de novo and
acquired trametinib resistance would be tissue specific. The overall hypothesis of
this dissertation was that identifying competitive adaptations of MAPK-active
neuroblastoma cells in response to MEK1/2 inhibition will guide the design of novel
combination therapies for relapsed neuroblastomas. Using a bimodal approach to
combination therapy design, we have identified a role for YAP in de novo trametinib
resistance, as well as validated a synergistic combination of novel inhibitors of YAP
activity and trametinib. In addition, we catalogued the activity of 3,045 compounds
as single-agents and in combination with trametinib in five RAS-MAPK
hyperactivated neuroblastoma cell lines and have begun to characterize the
efficacy of combined treatment with trametinib and statins. While these latter data
are not yet fully exploited, the screen provides a major resource for future drug
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development activities in the neuroblastoma research community (all data will be
made freely available prior to any publication).
The approaches adopted to test our central hypothesis were carved out of
lessons learned from the neuroblastoma field and the larger MEK1/2 inhibitor field.
In addition, these findings presented herein support our approach to identifying
novel combinations, both using innovative new compounds and FDA-approved
compounds identified via screening. Collectively, this body of work advances what
was known about neuroblastomas with hyperactivated RAS signaling and the
rewiring of oncogenic signaling as a result of MEK1/2 inhibition.

I.

YAP1 modulation of MEK inhibitor sensitivity
Here, we first define a role for the Hippo pathway protein YAP in determining

trametinib sensitivity in RAS-MAPK aberrant neuroblastoma cell lines. While basal
levels of YAP are low in the majority of neuroblastomas, we have definitively shown
that YAP activity can be induced by trametinib. With respect to the YAP-expressing
neuroblastoma cell lines, we present the first evidence of nuclear accumulation of
YAP induced by trametinib exposure. The exact mechanism underlying this shift
in cellular localization remains unclear. In BRAF V600E mutant melanoma cell
lines, the BRAF inhibitor vemurafenib was shown to induce YAP nuclear
translocation with concomitant formation of actin stress fibers (Kim, 2016). Actin
remodeling and actin-associated proteins are known to regulate YAP-Hippo
signaling via inputs including mechanical stress, contractile actomyosin,
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extracellular matrix stiffness, cell-cell junctions, and nuclear pores (Seo and Kim,
2018). However, phosphorylation of YAP could also be performed by upstream
core Hippo kinases or other cellular kinases such as Src; alternatively,
dephosphorylation could be altered by phosphatases such as PTPN14, in which
inactivating mutations have been identified in relapsed neuroblastomas (Seo and
Kim, 2018; Eleveld, 2015). Further investigation of this mechanism of YAP
phosphorylation and cellular localization will be critical to understanding the
interplay between the RAS-MAPK and Hippo pathways in neuroblastoma.
Using CRISPR-Cas9 gene editing, we generated four isogenic clones in
NLF cells (NF1 splice variant) and observed an 8-10-fold increase in trametinib
sensitivity over 72-hours. Conversely, we overexpressed a constitutively-active
form of YAP (YAP-5SA) in low-YAP expressing RAS-hyperactive cell lines and
demonstrated that YAP-5SA induced trametinib resistance. Taken together, these
two observations show that YAP activity in RAS-MAPK cell lines is a predictive
biomarker of trametinib sensitivity. However, we do not think that endogenous YAP
expression dictates sensitivity to single-agent trametinib, but rather induction of
YAP expression and nuclear translocation upon the selective pressure of MEK1/2
inhibition in hyperactivated RAS pathway cells. For example, SKNAS and NLF
cells have moderate-high YAP expression, yet they are extremely sensitive to
trametinib, with IC50 values of 10 nM and 20 nM, respectively. Rather, changes in
the regulation of YAP can provide a competitive advantage to MEK1/2 inhibition
that we seek to better understand.
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Using RNA sequencing, we defined gene signatures enriched in trametinibtreated YAP1 knockout cells. Using gene set enrichment analysis (GSEA), we
determined that E2F and MYCN gene sets were significantly downregulated in
response to combined YAP1 knockout and MEK1/2 inhibition. The connection
between E2F and YAP has been reported in other studies (Kapoor, 2014),
although there are several important distinctions. First, ChIP-qPCR was used to
confirm the co-occurrence of YAP/TEAD2 and E2F transcription factors at the
promoters of cell cycle genes in KRAS G12D mutant pancreatic ductal
adenocarcinoma cells (Kapoor, 2014). While we were not able to confirm the
enrichment of YAP or TEAD at the promoter of E2F genes, previous reports in
neuroblastomas that describe MYCN regulation of E2F expression suggests that
MYCN may play a more central role in our findings (Strieder V, 2003). Although
the model used for RNA seq does express MYCN, the majority of RAS-driven
neuroblastomas express high MYC, which is likely why we detected an enrichment
of the MYC gene signature in our RNA sequencing results. Furthermore, YAP
knockdown in vemurafenib-resistant BRAF V600E mutant melanoma cells
revealed enrichment of the E2F1 gene signature, as well as EGFR, EZH2, and
MYC gene signatures (Kim, 2016). In our analyses, E2F and MYC were the top
gene signatures enriched in the trametinib-treated YAP1 null-specific dataset.
While these results do point to a similar mechanism observed in Chapter 2, our
findings are specific to MEK1/2 inhibition and has significant implications in the
fields of neuroblastoma and MEK1/2 inhibitor research. In the same study that
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identified E2F1 gene signature changes in response to YAP knockdown, the
serine-threonine kinase TESK1, which promotes actin stress fiber formation via
Cofilin phosphorylation, was identified as a synthetic lethal target in vemurafenibresistant melanoma (Kim J, 2015). Further investigation of TESK1 and other
potential intersections between the RAS-MAPK and Hippo-YAP pathways will be
crucial to developing a deeper understanding of this mechanism in neuroblastoma
and defining translatable combinatorial therapeutic strategies.

II.

YAP1-TEAD as a therapeutic target
Our findings demonstrating the role of YAP in intrinsic trametinib resistance

was further validated upon discovering synergy between dual inhibition of MEK1/2
and YAP activity. The innovative efforts by Vivace Therapeutics generated novel
pharmacological inhibitors of TEAD palmitoylation as a proxy for the inhibiting
YAP-TEAD transcriptional output (Tang, 2019). As described previously, these
small

molecule

inhibitors

bind

within

a

pocket

and

prevents

TEAD

autopalmitoylation necessary for YAP-TEAD binding and transcriptional activity
(Chan, 2016; Noland, 2016). The lack of specific and selective inhibition of YAP
was the primary limitation prior to the discovery of this class of compounds, as
verteporfin was considered nonspecific and potentially toxic at concentrations
necessary for anti-YAP activity (Liu-Chittenden, 2012; Liu, 2019). Based on the
extensive literature reporting that TEAD is required for YAP oncogenic activity, we
entered into a collaboration with Vivace Therapeutics to perform the first
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combination studies with three proprietary compounds (Vassilev, 2001; Zhao,
2007; Zhang, 2008; Liu-Chittenden, 2012, Shi, 2017; Holden, 2018). In this
dissertation, I am unable to provide mechanistic details on the specificity of each
of the compounds studied due to a confidentiality agreement, but these details will
be forthcoming in future publications.
We have shown that, as predicted, each of the three Vivace compounds
(VT101, VT102, and VT103) showed no cytotoxicity in RAS-MAPK aberrant or
MYCN amplified (and RAS-MAPK wildtype) neuroblastoma cell line models. This
was expected as the isogenic YAP1 knockout cell lines discussed in Chapter 2
displayed varying levels of subtle (but reproducible) growth delay, particularly the
pooled sgYAP1 population which displayed minimal growth delay. Additionally,
TEAD palmitoylation inhibitors are only targeting one role of many performed by
YAP within the cell. Discrepancies between the effects of these inhibitors
compared to YAP1 knockout could be partially due to alternate YAP functions or
transcriptional partners which may affect cellular growth (Holden, 2018), or the
relative potency of these compounds compared to precise depletion by gene
editing.
Due to their recent discovery, there are no data describing combinations
studies with TEAD palmitoylation inhibitors in vitro or in vivo. Here, we show that
the combination of VT101 and trametinib is synergistic across three RAS-MAPK
hyperactivated cell lines, while VT102 and trametinib was primarily antagonistic.
With respect to VT101 and trametinib, these results are extremely encouraging
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and serve as a further validation of the data presented in Chapter 2. Importantly,
Vivace Therapeutics will be providing compounds for in vivo testing of this
combination as soon as their medicinal chemistry modification to these tool
compounds

create

molecules

with

improved

pharmacologic

properties.

Furthermore, the striking discordance between the effect of VT101 and VT102 in
combination with trametinib is intriguing and will provide mechanistic insights once
the company releases the compound structures and TEAD1-4 specificity (or
promiscuity) can be revealed. We posit that this difference is due to the differing
specificity for each of the four TEAD family members, which would potentially
implicate a specific TEAD transcription factor in YAP-driven de novo trametinib
resistance in relapsed neuroblastoma.

III. Alternate MEK inhibitor drug combinations
We generated two unique and valuable datasets in our high throughput
combination drug screen that we plan to make freely available to the academic
community. First, our dataset ranking trametinib drug combinations will serve as
an incubator for novel hypotheses for further preclinical validation. In parallel, the
high-throughput screen generated single-agent data which describes the effect of
each library compound alone on cell viability. This single-agent dataset could
reveal novel potent inhibitors of neuroblastoma cell lines and serve as a reference
guide for future drug development projects. One limitation of this study is that the
screen was only performed as one replicate, so each data point representing
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single-agent and combinatorial responses is N=1. This is not ideal because of the
potential biological and technical variation that could bias our results, but the size
and scale of the screen enabled us to profile an enormous collection of drugs. We
think that future screens should include additional replicates will improve the
reproducibility of the screen and streamline candidate drug selection.
Nevertheless, the high-throughput screen analysis we performed will serve as a
useful resource for trametinib combination drug design, as well as for
understanding the activity of a vast library of across five cell lines.
We have presented two separate in vitro validations of two categories of
drugs: HMG-CoA Reductase inhibitors, or statins, and epigenetic inhibitors. We
find that the combination of two different statins, atorvastatin calcium and
lovastatin, show synergy with trametinib in a panel of RAS-MAPK mutated
neuroblastoma cell lines. In our validations of trametinib and epigenetic inhibitors,
including inhibitors of HDAC6, EZH2, and DOT1L, the results were inconsistent,
and no synergy was definitively identified. A survey of the literature lends credence
to these observations that suggest the combination of a MEK1/2 inhibitor and a
statin may be more viable as a therapeutic regimen to improve MEK1/2 inhibitor
efficacy (Hindler, 2006; Cerezo-Guisado, 2007; Iizuka-Ohashi, 2018). Statins have
been shown to be well-tolerated and inexpensive and have even been shown to
play a role in cancer prevention in adults in a dose-dependent manner (Gronich
and Rennert, 2013; Taylor, 2008; Kuoppala, 2008; Sleijfer, 2005; Karp, 2008). On
the other hand, high dose statins have been reported to cause higher incidences
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of hepatocellular, thyroid, and pulmonary cancers (MacDonald, 1988; Robison,
1994). Our results suggest that the most synergistic combinations of MEK1/2 and
statins occur with high statin concentrations. Great care would be required to
protect patient safety while also ensuring that statin levels in the blood are
sufficiently high to elicit an anti-tumor effect. While this is a potentially interesting
result, we do not consider it readily translatable and trametinib-statin combinations
are not being pursued for clinical development.
The medical and pediatric oncology fields have struggled to find truly
synergistic combinations for cancers with mutations in the MAPK pathway.
Trametinib and other MEK1/2 inhibitors are being tested in the setting of mutated
receptor tyrosine kinases like EGFR or ALK with specific inhibitors of these
hyperactivated proteins. Empiric combinations with autophagy inhibitors and
immune checkpoint inhibitors are also being pursued. However, MAPK pathway
mutations are mutually exclusive of ALK mutations in neuroblastoma, and there is
little evidence for activity of drugs like chloroquine and the myriad of new immune
checkpoint inhibitors. This is one of the most difficult problems in oncology drug
development, and our screen’s limited translational success to date is likely not too
surprising, but we were hoping to find an autonomic neuronal-based oncogenic
vulnerability unique to this disease that we uncovered. Making these data publicly
available will increase the chance that unique discoveries from the screen will
impact patients in the not too distant future.
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IV. Future Directions
This study utilized a dual approach to study the signaling vulnerabilities
adopted in response to MEK1/2 inhibition in RAS hyperactivated neuroblastomas
and to design combination drug therapies for further preclinical validation. The
work presented in this dissertation has only begun to understand the complex
signaling dynamics under the pressure of MEK1/2 inhibition. Further investigations
are warranted to develop a clinically effective combination for treating relapsed
neuroblastoma. First, the observation of trametinib-induced nuclear translocation
of YAP protein is intriguing and may provide insight into the biology of relapsed
neuroblastoma, especially MAPK-activated cases subjected to MEK1/2 inhibitors.
To accomplish this, it would be useful to perform immunoprecipitation-mass
spectrometry (IP-MS) to capture and identify proteins interacting with YAP in the
presence and absence of trametinib treatment. If this experiment reveals novel
protein-protein interactions, then additional studies would be warranted to
understand this mechanism of YAP regulation. To test the hypothesis that actin
stress fiber formation may play a role in YAP nuclear accumulation,
immunocytochemistry of NLF and SKNAS cells stained for actin and YAP would
provide snapshots of this potential interaction. Co-treatment of trametinib with an
inhibitor of actin polymerization, such as cytochalasin D, could reveal whether
blocking the assembly of actin stress fiber formation affects YAP nuclear
localization. Furthermore, additional investigation could be done to elucidate the
mechanism responsible for the cooperativity between MEK1/2 inhibition and YAP
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knockdown. One approach to studying this could focus on the role of E2F and
MYC(N) in the combination of trametinib and YAP1 loss using ChIP-seq of TEAD14, YAP, E2F1, and MYC and MYCN. This experiment would illuminate the
transcriptional dynamics and determine whether YAP-TEAD function in concert
with E2F or MYCN, or rather compensate for the loss of E2F or MYCN in response
to trametinib. Although this dissertation primarily focuses on downstream effectors
of the Hippo pathway, it may be important to modulate the expression of upstream
Hippo pathway kinases MST1/2 and LATS1/2 in NLF and SKNAS cells to fully
discern the role of the core Hippo pathway components.
The results presented in Chapter 3 lay the groundwork for further preclinical
and clinical development of a combination of trametinib and a TEAD palmitoylation
inhibitor. We currently think this is the most likely combination to be translated to
a clinical trial in the next 1-2 years, and the collaboration with Vivace is active and
highly collaborative. To ensure on-target activity of the TEAD palmitoylation
inhibitors, NLF and SKNAS YAP1 knockout cell lines could be used with the
hypothesis that the loss of YAP expression would ablate the effects of the inhibitors
on cell viability. If these validations continue to show synergy between TEAD
palmitoylation inhibitors and trametinib, it will be necessary to test the combination
in a full in vivo study in NLF, SKNFI, and SKNAS xenograft models, as well as
carefully selected PDX models from our growing armamentarium of these precious
reagents (https://www.biorxiv.org/content/10.1101/566455v1). It will be important
to assess the efficacy of the combination, but also determine any toxicity related
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to in vivo inhibition of YAP-TEAD activity. We plan to test Vivace’s next generation
of compounds which are expected to be more specific for individual TEAD proteins
and be optimized for in vivo testing in Q4 of 2019. As this collaboration matures,
we expect to demonstrate improved efficacy in preclinical studies and deliver a
final combination therapy for inclusion in a clinical trial at the Children’s Hospital of
Philadelphia.
Based on our preliminary results from the high-throughput trametinib
combination drug screen, the observation of synergy between trametinib and
statins is an interesting result but unlikely to be clinically meaningful and will not
be pursued further. Rather, our efforts will focus on evaluating other top trametinib
combinations. Ultimately, including additional replicates of the full screen or of
smaller subsets, such as cancer-specific compounds, would improve the ability of
our analysis to detect true positives and eliminate false-positive combinations. We
plan to select a subset of top performing candidates for combination and perform
a validation screen. In this screen, cells would be treated with each candidate
compound over a 6-dose concentration range in combination with trametinib to
produce dose-response curves, from which IC50 values could be extrapolated
(Guo, 2017). In parallel, we will fully analyze the single-agent response data
collected in the screen for potential new insights into neuroblastoma therapeutic
vulnerabilities.
In sum, this body of work represents the first foray into the design of
trametinib drug combinations for RAS-MAPK pathway activated neuroblastomas.
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Insights gleaned from Chapters 2, 3, and 4 have significant implications in the
Hippo-YAP, RAS-MAPK, and neuroblastoma fields of research. We have
confirmed the role of YAP in intrinsic resistance to trametinib and validated a novel
TEAD-YAP inhibitor as a synergist therapeutic combination with MEK1/2 inhibition.
We also present a vast dataset profiling the activity of over 3,000 trametinib drug
combinations, with early preclinical validations indicating synergy between
trametinib and HMG-CoA Reductase inhibitors. In doing so, we have laid the
groundwork for continued exploration of both combination therapy approaches to
address the critical unmet need of new therapeutic options for relapsed
neuroblastoma.
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APPENDIX: Additional Published Manuscript
I. Genetic Susceptibility to Neuroblastoma
This section has been published: Tolbert, V.P.*, Coggins, G.E.*, Maris, J.M.
(2017). Genetic Susceptibility to Neuroblastoma. Curr Opin Genet Dev: 81-90.
Abstract
Until recently, the genetic basis of neuroblastoma, a heterogeneous neoplasm
arising from the developing sympathetic nervous system, remained undefined. The
discovery of gain-of-function mutations in the ALK receptor tyrosine kinase gene
as the major cause of familial neuroblastoma led to the discovery of identical
somatic mutations and rapid advancement of ALK as a tractable therapeutic target.
Inactivating mutations in a master regulator of neural crest development, PHOX2B,
have also been identified in a subset of familial neuroblastomas. Other high
penetrance susceptibility alleles likely exist, but together these heritable mutations
account for less than 10% of neuroblastoma cases. A genome-wide association
study of a large neuroblastoma cohort identified common and rare polymorphisms
highly associated with the disease. Ongoing resequencing efforts aim to further
define the genetic landscape of neuroblastoma.

INTRODUCTION
Neuroblastoma is the most common solid extracranial malignancy of
childhood, accounting for about 7% of all cancers in children under the age of 15
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(Howlader N, 2011). It is the most common cancer in the first year of life, with a
median age of diagnosis of 17 months (Howlader N, 2011; London WB, 2005). It
is a cancer of the developing sympathetic nervous system, arising in the adrenal
medulla or paraspinal ganglia (Hoehner JC, 1996). Approximately 65% of these
tumors present in the abdomen, along with the neck, pelvis and chest (Maris JM,
2007). Clinical course can vary widely, with infants often having spontaneous
regression of the tumor without chemotherapy (Carlsen NL, 1990; Cole WH, 1956;
Yamamoto K, 1998; Hero B, 2008), while older children generally have a poor
prognosis despite highly intensive chemotherapy, radiation therapy, and
immunotherapy (Maris JM, 2007). Demonstrating the phenotypic heterogeneity of
neuroblastoma, low-risk patients have a greater than 95% survival probability
whereas high-risk patients have a 40–50% probability of long-term survival
(Oberthuer A, 2015; Maris JM, 2010). It has been known for some time
that MYCN amplification in tumors portends a poor prognosis (Schwab M, 1983;
Brodeur GM, 1984; Seeger RC, 1985), and thus is used as a biomarker for
treatment stratification. Recently, there has been significant effort made to better
classify subgroups of patients based on age, and tumor spread, genomics and
differentiation (Brodeur GM, 1993; Cohn SL, 2009; Cecchetto G, 2005; Monclair
T, 2009; Deyell RJ, 2011). The International Neuroblastoma Risk Group (INRG)
classification has led to 16 statistically distinct risk groups based on clinical and
molecular features which has made prognosis more accurate for patients and
helps guide physicians on treatment regimens (Cohn SL, 2009).
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Significant progress has been made recently in the understanding of the
heritability of neuroblastoma through linkage scans of families with the disease and
genome-wide association studies (GWAS) of sporadic cases (Table 1). The
primary advantages of GWAS over previous methods are that no assumptions
about candidate genes are necessary, variations can be localized precisely, and
no testing in families or family members is required (Hirschhorn JN, 2005). From a
clinical standpoint, it is clear that improvement must continue to be made in
defining novel therapeutic approaches to neuroblastoma as it continues to account
for 12% of childhood cancer mortality (Maris JM, 2010), with advancement
especially crucial in high-risk patients (Tonini GP, 2012). One starting point to
develop optimal treatments is to understand the underlying genetic alterations that
initiate tumorigenesis. We review here the current understanding of the genetic
susceptibility of neuroblastoma.
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Table 1: Summary of neuroblastoma susceptibility loci. A majority of this
cohort of genomic loci are significantly associated with distinct neuroblastoma
phenotypes, while some remain to be characterized. P values and Odds Ratios
(ORs) are combined values between discovery and replication studies from the
original publication. Predicted mechanisms on protein function are indicated as
loss of function, gain of function, or currently unknown. MAF = minor allele
frequency.

Familial Neuroblastoma
About 1–2% of neuroblastoma is inherited in an autosomal dominant
fashion within families (Knudson AG, 1972; Kushner BH, 1986; Dodge HJ, 1945;
Chompret A, 1998). As with many cancer predisposition syndromes, patients often
have multiple primary tumor sites and an earlier age of onset. The disease is
typically highly penetrant, but there is variability and unaffected obligate carriers
are often observed (Knudson AG, 1972; Kushner BH, 1986; Mosse YP, 2008).
Neuroblastoma families often show significant clinical variability in severity of
disease, with low- and high-risk cases observed in the same pedigrees (Hardy PC,
1972; Gerson JM, 1974; Wong KY, 1971; Bergstrom JF, 1974; Brodeur GM, 2003).
While rare, these families provide a unique opportunity to learn about genetic
drivers of neuroblastoma.
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The first gene found to predispose to neuroblastoma was identified in
families affected with neuroblastoma along with Hirschsprung disease and/or
congenital central hypoventilation syndrome (also known as “Ondine’s Curse”).
These disorders of neural crest-derived cells are known as neurocristopathies and
are occasionally seen coincident with neuroblastoma (Bolande RP, 1997; Bower
RJ, 1980; Michna BA, 1988; Roshkow JE, 1988; Stovroff M, 1995). Amiel and
colleagues identified loss of function mutations in the paired-like homeobox 2B
(PHOX2B) gene in the majority of patients with congenital central hypoventilation
syndrome after sequencing this candidate gene (Amiel J, 2003, Weese-Mayer DE,
2003). This gene was of interest because the PHOX2B transcription factor is
essential during development of the autonomic nervous system. Germline
mutations in PHOX2B were subsequently found in a small proportion (~10%) of
pedigrees

with

familial

neuroblastoma,

making

this

the

first

bone

fide neuroblastoma predisposition gene (Trochet D, 2004; Mosse YP, 2004). As
expected, the families with PHOX2B mutations also had variable penetrance of
each of the component neurocristopathies, with non-polyalanine repeat expansion
mutations (NPARM) typically lead to the most severe phenotype (Heide S, 2016;
Nagashimada M, 2012).
In order to identify additional hereditary predisposition genes in the familial
neuroblastoma cases, a genome-wide linkage scan at 6,000 single nucleotide
polymorphisms (SNPs) was undertaken in 20 neuroblastoma families (Mosse YP,
2008). A linkage signal was found and narrowed down to chromosome bands
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2p23–p24,

which

contained
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genes

including

MYCN.

This

known

neuroblastoma oncogene was resequenced in all probands, but no mutation was
found. The anaplastic lymphoma kinase (ALK) is also in this region and had been
previously identified as a potential oncogene in this malignancy (OsajimaHakomori Y, 2005; George RE, 2007) as well as in other cancers through active
translocations and point mutations (Griffin CA, 1999; Jazii FR, 2006; Morris SW,
1994; Rikova K, 2007; Soda M, 2007; Inamura K, 2008; Wang YW, 2011; Murugan
AK, 2011). When ALK was resequenced, three distinct mutations were found in
this gene in eight discrete families (Mosse YP, 2008). Subsequent studies have
confirmed that about 80% of families with neuroblastoma harbor mutations in ALK.
Mutations in ALK were also found to be somatically acquired in about 10% of all
cases of neuroblastoma (Mosse YP, 2008; Janoueix-Lerosey I, 2008; George RE,
2008; Chen Y, 2008). ALK is a receptor tyrosine kinase, and all of these were
activating mutations in the tyrosine kinase domain that caused constitutive
phosphorylation and were predicted to be oncogenic drivers (Mosse YP, 2008).
While Knudson and Strong’s prediction of a “two-hit” model has held true for most
hereditary cancers (Knudson AG, 1972), these susceptibility genes are usually
tumor suppressor genes. In contrast, ALK was the first oncogene mutation shown
to cause a familial pediatric cancer. The Mosse lab has subsequently
biochemically characterized each of the germline and somatic mutations, and there
is a correlation between penetrance and mutation type (Bresler SC, 2014; Bresler
SC, 2011). For example, the R1275Q mutation leads to near complete penetrance
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in families and was shown to be one of the most activating mutations tolerated in
the germline, whereas the G1128A is more weakly activating and is correlated with
an approximate 25% likelihood of developing neuroblastoma. Interestingly, the two
most highly activating hotspot mutations acquired somatically (F1174* and
F1245*) were each observed in the germline once, but in the setting of
neuroblastoma with severe neurocognitive defects and brain stem abnormalities,
further emphasizing the genotype-phenotype relationship as well as the critical role
plays in normal neurodevelopment (de Pontual L, 2011). Genetic testing for
both ALK and PHOX2B are currently available for identifiying genetic susceptibility
and

informing

decisions

about

screening

other

family

members

(http://www.ncbi.nlm.nih.gov/sites/GeneTests/).
ALK was quickly identified as a potential pharmacologic target in
neuroblastoma when knockdown of ALK resulted in growth inhibition in all
neuroblastoma cell lines with ALK mutations and some with wild-type ALK (Mosse
YP, 2008). Further testing with an ALK small molecule inhibitor, crizotinib, showed
profound sensitivity in vitro and in vivo to the drug in a panel of neuroblastoma cell
lines and xenografts, respectively, with certain mutations and ALK amplification
(Bresler SC, 2011; Schonherr C, 2011; Heuckmann JM, 2011; Carpenter EL,
2012). Based on these data, only 18 months after ALK was discovered as a
neuroblastoma oncogene, the Children’s Oncology Group initiated a Phase I/II
clinical trial testing crizotinib in patients with relapsed pediatric solid tumors and
anaplastic large cell lymphoma (ALCL) (www.clinicaltrials.gov, Identifier:
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NCT00939770). Toxicity has remained low, and seven patients with ALCL and two
patients with neuroblastoma have had complete responses as the trial continues
(Mosse YP, 2013). This is a hallmark example of how identifying genetic
susceptibility can be quickly advanced for clinical benefit.
However, there are some families that do not show mutations
in ALK or PHOX2B, thus the search for additional familial neuroblastoma gene
continues. Whole exome analysis of one family with two affected cousins and two
healthy members showed a mutation in GALNT14 predicted to be functionally
damaging, but continued efforts are necessary to further define this familial variant
(De Mariano M, 2015). In parallel, germline mutations in TP53, SDHB, PTPN11,
APC, and NF1 have been reported to occur rarely in neuroblastoma patients
(Figure 1) (Birch JM, 2001; Hasle H, 2009; Mutesa L, 2008; Chantrain CF, 2007;
Schimke RN, 2010; Cascon A, 2008; Vandepoele K, 2008; Zhang J, 2015).
Neuroblastoma has also been reported to arise in complex congenital
malformation syndromes, such as the subtelomeric 1p36.3 or 11q23 deletions
(Isidor B, 2008; Mosse Y, 2003). The heritability of neuroblastoma remains only
partially understood, yet continued investigation is expected to reveal new insights
into familial neuroblastoma predisposition, including gene-gene and geneenvironment interactions.
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Figure 1: Graphical representation of genetic predisposition to
neuroblastoma. Known familial and sporadic predisposition genes have been
compiled into one summary figure across multiple studies. The familial mutations
are shown in the top left of the graph representing a very rare allele frequency
and high effect size. GWAS-discovered variations are in the bottom right corner
representing a higher allele frequency with a lower effect size. Continued
sequencing efforts are likely to uncover additional rare susceptibility variants
along this spectrum, of which dozens are predicted to be discovered to explain
the heritability of neuroblastoma.
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Genetic susceptibility to familial neuroblastoma
In familial neuroblastoma, there are rare mutations that lead to a high
probability of disease. For the 99% of cases that occur sporadically, a common
variant hypothesis proposes that common germline variations influence the
probability of disease occurrence, each with a low relative risk, but presumably
acting in concert. A large GWAS consisting of 720 neuroblastoma cases and 2,128
controls was undertaken in neuroblastoma as an unbiased method for discovering
these polymorphisms (Figure 2) (Diskin SJ, 2012). This original GWAS has been
expanded and replicated as additional patient samples have been accrued, leading
to the identification of DNA alleles significantly associated with high-risk and lowrisk neuroblastoma predisposition, including CASC15, BARD1, LMO1, LIN28B,
HACE1, DUSP12, DDX4, IL31RA, HSD17B12, NEFL, TP53, AND NBPF23 (Table
1) (Maris JM, 2008; Pandey GK, 2014; Bosse KR, 2012; Wang K, 2011; Oldridge
DA, 2015; Diskin SJ, 2012; Capasso M, 2014; Nguyen le B, 2011; Diskin SJ, 2009;
Gamazon ER, 2013). The discovery of these susceptibility loci demonstrates the
utility of interrogating GWAS signals for clues into the underlying biology driving
neuroblastoma genesis.
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Figure 2. Manhattan plot of high-risk neuroblastoma GWAS results across
multiple studies. Level of significance (−log10 transformed p values) for each
SNP along the genome in chromosomal order is plotted, and the corresponding
genes are labeled. Red line: genome-wide significance threshold based on
Bonferroni adjustment. Adapted from Diskin, et al. 2012.

Results from the initial GWAS identified three SNPs at chromosome 6p22
within a newly identified long noncoding RNA (lncRNA) annotated as CASC15
(Maris JM, 2008). Homozygosity for the risk alleles was significantly associated
with metastatic disease, amplification of MYCN oncogene in the tumors, and
patient

relapse.

Recently,

decreased

expression

of

the

truncated

isoform CASC15-S was associated with more advanced disease (Russell MR,
2015). Another lncRNA, NBAT-1 (CASC14), was shown to be located at the 6p22
susceptibility locus as well, and functional studies have shown that loss of NBAT1 promotes proliferation and invasion (Pandey GK, 2014). Subsequently, a GWAS
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restricted to high-risk neuroblastoma identified the BRCA-associated ring domain1 gene (BARD1) at chromosome 2q35 was identified as a susceptibility locus
(Capasso M, 2009). Six SNPs were discovered in three different N-terminal introns
of this gene. BARD1, along with its binding partner, breast cancer 1, early
onset (BRCA1), had been previously implicated in breast and other cancers, but
genetic variants in BARD1 had not been shown to lead to cancer susceptibility,
even in breast cancer (Wu LC, 1996; Irminger-Finger I, 2006; Hosking FJ, 2011).
Continuing efforts in BARD1 have found that an isoform, BARD1β, which lacks the
RING domain necessary for BRCA1 binding, is preferentially expressed in
neuroblastoma cell lines that are homozygous for the risk alleles (Bosse KR,
2012). Consistent with oncogenic behavior, knockdown of this isoform inhibits cell
growth, while overexpression leads to increased proliferation. Additionally,
BARD1β was found to stabilize the Aurora family of kinases in neuroblastoma cell
lines, suggesting a possible mechanism of action and potential therapeutic
strategy as Aurora kinase inhibitors are in clinical development for cancer (Bosse
KR, 2012; Ryser S, 2009).
This GWAS was expanded (2,251 neuroblastoma cases and 6,097
controls) and the gene LMO1 was shown to be significantly associated with highrisk neuroblastoma, which had previously been implicated in human cancer, but
not neuroblastoma. Four SNPs that were significantly associated with
neuroblastoma at chromosome 11p15.4 were within the LIM domain only 1 (LMO1)
gene (Wang K, 2011). This gene, along with LMO2, LMO3 and LMO4, encodes a
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cysteine-rich transcriptional cofactor that is preferentially expressed in the nervous
system (Su AI, 2004). This family of genes has been found to be critically involved
in leukemia (reviewed in Curtis DJ, 2010) and breast cancers (Sum EY, 2002;
Visvader JE, 2011; Montanez-Wiscovich ME, 2009), while LMO3 has been shown
to be oncogenic in neuroblastoma through its interaction with a neuronal-restricted
transcription factor (Aoyama M, 2005). These common variations in LMO1 were
found to be associated with high-risk disease and decreased survival (Wang K,
2011). Neuroblastoma tumors with LMO1 risk alleles were found to have increased
expression of LMO1, and depletion of LMO1in cell lines decreased growth while
forced over-expression increased growth (Wang K, 2011). This is consistent with
a gain-of-function role in tumor progression. Recent investigation showed that the
causal SNP resides in a super enhancer element within the first intron, with the
G>A transversion ablating a canonical GATA transcription factor binding site
(Oldridge DA, 2015). Investigators showed that the A allele was “protective”, as
there was no GATA binding, and not cis-mediated LMO1 transcription, providing
one of the first clear mechanistic insights into a genetic association.
By further expanding this GWAS to 2,817 neuroblastoma cases and 7,473
controls, two new association signals emerged at 6q16 in two different
genes, HACE1 and LIN28B (Diskin SJ, 2012). HACE1 encodes an E3 ubiquitin
ligase and has been identified as a tumor suppressor gene silenced in Wilms’
tumors, colorectal cancer, and gastric carcinoma (Anglesio MS, 2004; Hibi K,
2008; Sakata M, 2009). It has also been shown to suppress cell growth in human
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cancer cells, including a neuroblastoma cell line, by inhibiting cell cycle
progression during stress (Zhang L, 2007). LIN28B, a known oncogene, encodes
an RNA-binding protein that is developmentally regulated and blocks the
expression of the let-7 family of microRNAs (Piskounova E, 2011). High expression
of LIN28B and correlated low levels of let-7 have been observed in many human
cancers (Iliopoulos D, 2009; Vixwanathan SR, 2009). LIN28B and let-7 are
involved in stem cell differentiation, as overexpressing the former or inhibiting the
latter leads to the reprogramming of human and mouse fibroblasts into pluripotent
stem cells (Melton C, 2010; Yu J, 2007). In the GWAS, LIN28B was expressed at
significantly higher levels in neuroblastoma cell lines homozygous for the risk
allele, and this correlated with lower levels of let-7 and growth inhibition following
knockdown of LIN28B (Diskin SJ, 2012). In tumor samples, HACE1 expression
was significantly lower and LIN28B significantly higher in high-risk neuroblastomas
and were correlated similarly with worse overall survival. Mechanistic studies have
shown that LIN28B promotes increased expression of the oncogenic protein RAN,
which both converge on Aurora Kinase A (Schnepp RW, 2015). Increased activity
was shown to drive tumorigenesis, providing further evidence that targeting Aurora
kinases may provide a benefit to neuroblastoma patients (Carol H, 2011; Mosse
YP, 2012).
In an integrated proteomic-GWAS approach, Capasso identified three
SNPs significantly associated with neuroblastoma in the NEFL gene, encoding the
light chain neurofilament protein in which mutations are known in disorders of the
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peripheral nervous system (Capasso M, 2014). Overexpression of NEFL in cells
with a protective allele caused cells to adopt a more differentiated phenotype and
to have reduced proliferative capacity. The authors suggested that decreased
expression of NEFL alters the differentiation state of sympathetic neurons and may
predispose neuroblastoma (Capasso M, 2014).
After enriching the GWAS for patients with low-risk neuroblastoma, SNPs
in four genes, DUSP12, DDX4, IL31RA and HSD17B12, were discovered to be
significantly associated with this phenotypic subset (Nguyen le B, 2011). These
genes are different than those found in high-risk neuroblastoma, suggesting these
subtypes are likely genetically distinct and emphasizing the importance of robust
phenotypic information in GWAS efforts. These data further support the notion that
widely divergent neuroblastoma phenotypes are genetically predetermined.
A genome wide SNP scan for copy number variation (CNV) identified a
novel CNV at 1q21.1 that is associated with neuroblastoma, and they were able to
confirm deletions in this region by quantitative PCR and FISH (Diskin SJ, 2009). A
new neuroblastoma breakpoint family gene, NBPF23, was identified at this location
by a transcript that was similar to other genes in the family. This transcript is most
commonly expressed in fetal brain and sympathetic nervous system tissues, and
in neuroblastoma, its expression was correlated with this CNV. NBPF1 was
identified originally at the translocation breakpoint in the germline of a child with
neuroblastoma (Vandepoele K, 2008), and research continues to elucidate the role
of this family of genes in disease development.
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The prevalence of GWAS-associated genes has been further interrogated
among different ethnic groups. A follow up study to the previously
described BARD1 GWAS was carried out in African American children with
neuroblastoma looking at SNPs in the gene regions identified by the GWAS in
Caucasians (Latorre V, 2012). Two of the six SNPs found in BARD1 were also
significantly associated with neuroblastoma in the African-American cohort,
validating the original GWAS. Due to different patterns of linkage disequilibrium in
the two ethnicities, this effort narrowed the potential location of the causal variant.
Another study in patients of African descent identified an allele in a new gene,
sperm associated antigen 16 (SPAG16), associated with high-risk neuroblastoma
in patients of both African and European ancestry showing the potential of
discovering new associations by studying specific ethnic groups (Gamazon ER,
2013).
In the Oldridge manuscript noted above defining a mechanistic basis for the
LMO1 association, the protective T-allele was noted to be common in people of
European ancestry, but is largely absent in African and African-American
populations, which retain the G-allele (Capasso M, 2014). This may provide a
partial explanation for the more aggressive forms of neuroblastoma observed in
African-American patients. Altogether, these results indicate that ethnic
background may play a role in genetic predisposition and that therapeutic
approaches may require requisite tailoring.
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Collectively, these GWAS-discovered genes account for only a small
portion of neuroblastoma heritability, which remains poorly understood. It is likely
that further expansion of GWAS efforts will continue to uncover more susceptibility
genes that will confer risk in an additive manner. No epistasis was found when the
most significant SNPs from 2q35, 6p22, 11p15.4 and 1q21.1 CNV were studied
together (Wang K, 2011); however, specific clusters of combinations of these
SNPs were significantly associated with neuroblastoma (Capasso M, 2014).
Mechanistic insights are being discovered, but the underlying basis for most
statistical associations remain unknown. Neuroblastoma GWASs were expected
to discover genes that affect development of the sympathetic nervous system,
showing that common variants can lead to missteps in development and therefore
malignancies. Investigators are pursuing ongoing studies to model GWAS variants
and heritability in zebrafish and induced pluripotent stem cell models to understand
the biological consequences in neuroblastoma and investigate potential
therapeutic interventions.

Rare Variants
There are currently two main groups of germline DNA variations that
predispose to neuroblastoma: very rare genetic mutations leading to Mendelian
inheritance of familial neuroblastoma with a high penetrance, and common
variations that only increase risk of disease in small increments. These discoveries
thus far have only explained a small proportion of the heritability of neuroblastoma.
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While further expansion of the GWAS will continue to uncover more common
variants and genes important in the development of neuroblastoma, we suggest
that these discoveries lie on a spectrum with the middle ground only beginning to
be realized (Figure 1). These are rare germline variations or mutations with a lower
penetrance than familial disease but with a larger effect on predisposition than the
common SNPs. Owing to their rarity and the relatively small number of patients
with neuroblastoma, it has been difficult to identify these rare variants. Recently,
two rare germline variants in TP53 were found to be robustly associated with
neuroblastoma using the 1000 Genomes Project (The 1000 Genomes Project
Consortium, 2010) and an advanced imputation process elucidating associations
with SNPs not directly assayed on the limited arrays (Diskin SJ, 2014). Likewise,
germline

sequencing

has

identified

putative

damaging

mutations

in ALK, CHEK2, PINK1, BARD1 and APC1 in small percentages of patients with
neuroblastoma (Zhang J, 2015; Pugh TJ, 2013). As sequencing technology
improves and costs decrease, discoveries of additional rare variants are on the
horizon to define and characterize further the heritability of neuroblastoma. The
influence of germline mosaicism and epistatic interaction of de novo or inherited
mutations with GWAS-defined polymorphisms remains undefined.

Summary and Future Directions
Significant progress has been made in the last six years in describing the
genetic landscape of neuroblastoma and continuing studies will aim to further
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identify Mendelian susceptibility genes. This is already influencing clinical care as
genetic testing is available, and there are noninvasive screening methods to surveil
for disease in young children. Current recommendations suggest that children with
a known damaging germline mutation in ALK or PHOX2B based on familial
pedigrees should undergo surveillance with every 3-month ultrasonography and
urinary catecholamines until a minimum of age 5, if not beyond (Laug WE, 1978).
The main impact of GWAS studies to date is in identifying genes critical to
neuroblastoma progression and maintenance, thus uncovering potential
oncogenic vulnerabilities. With the discovery of ALK as an example, it is important
that translational approaches related to these genes be prioritized, as additional
targeted therapies for patients with neuroblastoma are essential to improving
survival. Future work to extend the discovery of germline polymorphisms to those
that influence response to therapy and impact co-morbidities such as hearing loss
also has the potential to improve patient survival and quality of life. The ultimate
goal of genomic studies in neuroblastoma is to inform precision medicine with
genetic evaluations to tailor clinical treatments and extend survival (Schnepp RW,
2015; De Mariano M, 2015). As additional patient samples are accrued over time,
future GWAS endeavors will be required to continue the discovery of additional
susceptibility alleles. Extensive further investigation, both computationally and in
designing better models for these rare genetically defined subsets, will be required
to translate these genomic discoveries into actionable targets for diagnosis and
treatment.
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